CONFERENCE PLANNING COMMITTEE
Ira J. Marion, MA  
Conference Chair  
Mark W. Parrino, MPA  
President  
American Association for the Treatment of Opioid Dependence, Inc.  
Carleen Maxwell, MPH  
Project Director  
American Association for the Treatment of Opioid Dependence, Inc.  
Angelina Budija  
Administrative Coordinator  
American Association for the Treatment of Opioid Dependence, Inc.  
Alexandra Springer  
Meeting Manager  
Talley Management Group, Inc.  
Wendy Stevens  
Tradeshow Manager  
Talley Management Group, Inc.

Board of Directors  
Mark W. Parrino, MPA  
President  
Ira J. Marion, MA  
First Vice-President  
George Stavros, MD  
Second Vice President  
Michael Rizzi  
Treasurer  
Jina K. Thalmann, LCSW  
Secretary  

Board Members  
Richard Bilangi, MS  
CT  
Roya T. Brown, MS  
LA  
Carol Butler, MA  
MD  
Brian Crissman, BA  
DC  
Eric Ennis, LCSW  
CO  
Steve Flora  
AL  
Richard Froncillo, LCDS  
PA  
Gregory Hardin, CADACII  
IN  
Edward J. Higgins, MA  
NJ  
Ron Jackson, MSW  
WA  
Edward G. Johnson, LPC  
SC  
Janice F. Kauffman, RN  
MA  
Jason Kletter, PhD  
CA  
Shirley Linzy, RN  
NV  
Kate Mahoney, LCSW  
IL  
Brian McCarron, DO  
MI  
Paul McLaughlin, MA  
CT  
Joel Millard, DSW  
UT  
Edward V. Ohlinger  
VA  
Stacey Pearce  
GA  
Carrie Perkins  
ME  
Galen E. Rogers, PhD  
MEXICO  
Keith E. Spare, MS, MDiv, LPC  
MO

2009 CONFERENCE COMMITTEES

Awards Committee
Jason Kletter, PhD - Committee Chair  
Stacey Pearce  
Michael Rizzi  
George Stavros, MD  
Jina K. Thalmann, LCSW

Hospitality Committee
Haynes – Committee Chair  
Dale Wallace-Thompson, MS  
Caroline Waterman, MA

International Committee
Michael Rizzi – Committee Chair  
Icro Maremmani, MD  
Ira J. Marion, MA  
Mark W. Parrino, MPA

Plenary Committee
Herbert Barish, MSW - Committee Chair  
Ira J. Marion, MA  
Robert B. Millman, MD  
Mark W. Parrino, MPA

Public Relations Committee
Daniel McGill – Committee Chair  
Dianne Henk  
Jim Mandler  
Nancy Moon  
Loretta Parsons-Poole

Volunteer Committee
Kathryn Williams, LMSW – Committee Chair  
Felice Bradford Richards, BA  
Celia Harewood, MA  
Marie Marciano, LMSW  
Glorice Sanders, RN  
Martin Ringer

Workshop Committee
Ron Jackson, MSW – Committee Chair  
Candace Baker, MSW  
Jennifer Fan, PharmD  
Belinda Greenfield, MA  
Petra Jacobs, MD  
Patti Juliana, ACSW  
Karol Kaltenbach, PhD  
Chris Kelly  
Judith Martin, MD  
Dana Moulton, CMA  
Susan Storti, RN  
Michael Rizzi  
Joan Zweben, PhD
Dear Colleagues, Patients, Advocates, Stakeholders and Friends:

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), and our hosts, the New York State Office of Alcoholism and Substance Abuse Services (OASAS) and COMPA – New York State’s Opioid Treatment Coalition, it is my great pleasure to welcome you to New York City, to the Hilton Hotel and to our 2009 AATOD Conference. Our planning committee and AATOD staff has worked hard to make AATOD’s 25th Anniversary Conference a truly memorable event. We gather together in very challenging times, with a new administration in Washington and a renewed hope for change for our field and certainly for those who rely on the care we provide. Our conference theme, “Treatment and Recovery: People and Outcomes” challenges us to think of those still in need of treatment, as well as our patients and is addressed in our conference program. As you review the Plenary, Workshop and Hot Topics as well as the pre-conference training opportunities, you will appreciate the efforts of our planners to provide you with a premier training and policy event focusing on opioid dependence and medication assisted treatment. Our conference respects the diversity in our field, and the difficult challenge in restoring lives, families and communities. It is my hope that as you plan your conference schedule, you make sure to allow time to see our beautiful city as spring is in bloom – Central Park, museums, Times Square, restaurant row – all just outside the Hilton’s front door.

AATOD and our planning Committee are well aware of the challenges we face as patients, staff, advocates, stakeholders and policy makers. As we convene in New York, critical issues confront OTPs, here and across the globe. We have thoughtfully tried to focus on our beginnings, the passion and concern we all have to provide recovery opportunities for our patients, while eliminating the stigma that pervades our treatment modality. Now, we face new challenges, transforming our programs to provide quality, individualized services with respect and dignity, incorporating evidence based practice and measuring what works and for whom. Our plenary sessions have been designed to focus on medication assisted treatment as a vital part of the continuum of care for those dependent on opioids. You will hear about the transformation process now ongoing in New York State, initiated by our OASAS Commissioner, Karen Carpenter-Palumbo. On Tuesday, CSAT Director Dr. H. Westley Clark will provide a guide to the integration of recovery oriented systems of care in OTP, joined by renowned recovery expert, William White and two individuals whose lives were changed by medication assisted treatment. Our closing plenary will look to our future and forge a pathway to fight the stigma that so easily discourages our patients and our staff, addressing ways to generate public support for our work.

I invite you to participate in all our sessions, to spend time in our exhibition hall, talking to the many vendors and exhibitors that support our field and view their offerings. I urge you to speak up at our hot topic roundtables making your voice and ideas heard. Attend the workshops, posters and other conference activities, packed with information and ideas to improve our programs. We’ve tried to provide activities of interest to everyone – pre-conference trainings, the open AATOD Board meeting Saturday afternoon, our Sunday Opening reception and, the memorable Awards Banquet, where ten people have been chosen to receive the Nyswander/Dole “Marie” award, this year presented by Ms. Anita Townley, secretary, friend and confidante for twenty years to Marie Nyswander and to Vincent Dole, and a medical maintenance patient since that program began. In addition, at this banquet, the AATOD Board will confer our “Friend of the Field” award and the “Richard Lane/Robert Holden Patient Advocacy Award.”

I am confident that this conference will be a memorable, moving event from the moment you arrive to the Closing Plenary Session. For those who wish, tours of some of our NYC clinics will also be available just after the Closing session. On behalf of the many people who have worked so hard to construct this exciting conference event, I welcome you to the Big Apple, New York, the “city that never sleeps”. I extend my heartfelt thanks to the staff of AATOD, our Committee Chairs and committee members and to Talley Management for helping to make this memorable conference.

Enjoy the conference, the social events and our wondrous New York City. I look forward to meeting many of you.

Ira J. Marion, MA
2009 Conference Chair
## Conference at a Glance

All events and times listed are subject to change!

<table>
<thead>
<tr>
<th>DAY</th>
<th>DATE</th>
<th>TIME</th>
<th>EVENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>April 25</td>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:00 PM</td>
<td>The Certified Methadone Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Buprenorphine and Office-Based Treatment of Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:00 PM</td>
<td>Performance Improvement in Opioid Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 5:00 PM</td>
<td>The Physician Clinical Support System</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:45 PM</td>
<td>AATOD Open Board Meeting</td>
</tr>
<tr>
<td>Sunday</td>
<td>April 26</td>
<td>7:30 AM – 7:30 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 12:30 PM</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>Opioid Treatment Program Accreditation Town Hall Meeting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 5:30 PM</td>
<td>State Opioid Treatment Authorities’ Meeting (Closed Session for State and Federal Officials)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 AM – 12:00 PM</td>
<td>Opioid Analgesics and Pain in Opioid Dependence Treatment - New Research Findings, Clinical Implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 4:00 PM</td>
<td>Risk Management in the OTP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Hepatitis Education for Opioid Treatment Providers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>European Opiate Addiction Treatment Association (EUROPAD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Trends and Changes in the Quality Framework Called “Accreditation”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:00 PM – 5:00 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Monday</td>
<td>April 27</td>
<td>7:30 AM – 7:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 4:30 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Opening Plenary Session - Meeting Challenges in Turbulent Times: New York State’s Transformed Treatment System and Continuum of Care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Session/Hot Topic Round Tables</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 4:00 PM</td>
<td>Exhibitors Networking Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4:00 PM – 5:30 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30 PM – 8:00 PM</td>
<td>Town Hall: A Continuing Community Discussion of How OTPs and the Treatment Community Can Work Together to Prepare for the Next “Service Discontinuity”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 8:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Tuesday</td>
<td>April 28</td>
<td>7:30 AM – 3:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:45 AM</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 1:30 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 1:30 PM</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Middle Plenary Session - Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 9:30 PM</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 PM – 10:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Wednesday</td>
<td>April 29</td>
<td>7:00 AM – 1:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 9:30 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:45 AM – 11:15 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30 AM – 12:45 PM</td>
<td>Closing Plenary Session - Policy, Programs and People</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:30 PM</td>
<td>Clinic Tours</td>
</tr>
</tbody>
</table>
PRE-CONFERENCE SESSIONS Saturday, April 25, 2009

8:00 AM - 5:00 PM Nassau Suite

The Certified Methadone Advocate (CMA) Training Course

Walter Ginter, CMA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY
Joycelyn Woods, MA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY
J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL
Nicholas Reuter, MPH, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Rockville, MD
Belinda Greenfield, EdM, CRC, NYS OASAS, Teaneck, NJ
Dana Moulton, MATS, National Alliance of Methadone Advocates (NAMA); MA NAMA, Marlboro, MA
Howard Lotsof, BFA, National Alliance of Methadone Advocates (NAMA); Dora Weiner Foundation, Staten Island, NY
Donna Schoen, CMA; LI NAMA, Long Island, NY
Kerry Wolf, ADN, ARM Texas; We Speak Methadone Forum (NAMA), Cedar, TX

The leading advocate organization for methadone, the National Alliance of Methadone Advocates (NAMA), developed this training, believing that professionals, patients and families of patients can come together to work for a better understanding of methadone and medication assisted treatment. Previous trainings have shown that participants – both professionals and patients alike are equally empowered. Therefore we encourage both patients and non-patients to become Certified Methadone Advocates (CMA). This training is designed for non-clinicians and provides a basic understanding of the physiology of addiction and the use of medications to treat it (i.e. methadone and buprenorphine). Regulations at the federal, state and local levels are explained in simple terms for non-policy makers. Participants will come away with the initial tools for basic advocacy to grow and develop into successful advocates. The course involves 8 hours of rigorous training and fulfills the training requirement for Certification as a Methadone Advocate (CMA).

With these goals in mind, the course presentation is constituted as follows:

- **Regulations and Accreditation** – Current regulations explained by the federal agency that oversees methadone and buprenorphine treatment.
- **State Methadone Authority** – New York State regulations explained by the NY SMA provide a view of working within state systems.
- **Hands On Advocacy** – Basic tools to work as an advocate and how to manage simple issues that advocates are confronted with including educating patients about their rights, handling grievances, legal issues and working within communities to benefit patients and treatment.
- **Advocacy and The Media** – Responding to negative media in newspapers, television, movies, etc. and writing response letters and letters to the editor.
- **Systems Advocacy** – Using advocacy to change policy and working within state and federal systems to improve the rights of patients.
- **Advocacy Campaigns** – Developing an advocacy campaign to target an issue or respond to negative and incorrect information about medication assisted treatment.
- **The Certified Methadone Advocate (CMA)** – What is a Certified Methadone Advocate, ethics of advocacy and the mechanism of certification and how it will professionalize those committed to advocacy.

Candidates for certification must register with NAMA prior to the conference. On-site registration will be between 8:00am and 9:00am at the NAMA table in the foyer of the Nassau Suite. NAMA cannot guarantee a place to anyone who did not pre-register.

There is a separate registration fee of $50.00 for this pre-conference event. The fee includes all materials, 2008/09 membership in NAMA, and the application for CMA. Lunch is not provided.

Sponsored by the National Alliance of Methadone Advocates (NAMA).
8:00 AM - 5:30 PM  *Beekman Parlor & Sutton North*

**Buprenorphine and Office-Based Treatment of Opioid Dependence**

**Edwin A. Salsitz, MD, Beth Israel Medical Center, New York, NY**

**Petros Levounis, MD, The Addiction Institute of New York, St. Luke’s & Roosevelt Hospitals; Columbia University College of Physicians & Surgeons, New York, NY**

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV and V narcotic medications for the treatment of opioid addiction in an office-based setting as part of the Drug Abuse Treatment Act (DATA) 2000. Physicians qualify after completion of not less than eight (8) hours of approved training. This course satisfies the DATA 2000 eight-hour training requirement. Certificates will be provided to each physician who completes the training confirming the eight hours of training. Certificates may be mailed to the Secretary of Health and Human Services along with a Request for Waiver of the special registration requirements defined in the Controlled Substances Act.

The goal of this program is to acquire the knowledge and skills needed to provide optimal care to opioid dependent patients.

Topics covered in the program are:

- **Overview of opioid dependence:** describes the rationale and effectiveness of opioid pharmacotherapy in the treatment of opioid dependence.
- **Buprenorphine efficacy and safety:** summarizes the literature on the efficacy and safety of buprenorphine treatment.
- **Legislative changes:** summarizes the law, Drug Addiction Treatment Act of 2000 (DATA 2000), that allows for the treatment of opioid dependence in office-based settings.
- **Patient selection:** describes the essential aspects of assessing and selecting patients appropriate for office-based opioid treatment.
- **Clinical use of buprenorphine:** describes induction, stabilization and maintenance protocols for treating opioid dependent patients with buprenorphine.
- **Non-pharmacological interventions:** describes the efficacy, components and role for non-pharmacological treatments for opioid dependence.
- **Medical and psychiatric conditions in opioid dependent patients:** summarizes the common medical and psychiatric co-morbidities including HIV/AIDS, hepatitis B and C, depression and anxiety found in opioid dependent patients.
- **Special treatment populations:** describes the management of pain in patients with addictive disorders, and the management of adolescents and pregnant women with opioid dependence.
- **Office procedures:** describes and be able to apply clinical tools (e.g. treatment contacts, consents and protocols) needed to set up office-based treatment with buprenorphine. Describes the important confidentiality and record keeping requirements for treating opioid dependent patients in office-based settings.

This program is recommended for physicians with experience and/or interest in treating opioid dependence. This program features didactic and case-based small group discussions. It is also recommended for primary care, psychiatric, HIV, pain and addiction medicine physicians.

**Sponsored by the American Society of Addiction Medicine. Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.**

8:30 AM - 5:00 PM  *Sutton Center & South*

**Performance Improvement in Opioid Treatment**

**Robert A. Johnson, MEd, DB Consulting, Columbia, MO**

**Brenda Gilliam-Jones, MPA, DB Consulting/Johnson, Bassin and Shaw, Inc., Orlando, FL**

**Module One - Introduction to the Workshop:**

The purpose of this module is to conduct an overview of the workshop and to set the tone for the training by creating a positive environment for discussion and for learning about performance improvement in opioid treatment facilities.

**Module Two - What Is Performance Improvement?**

The goal of this segment of the workshop is to create a common understanding of the terms and definitions that are used in the field of performance improvement and that will be used during the workshop.

**Module Three - Developing an Organizational Culture for Performance Improvement**

The purpose of this module is to review the type of organizational culture required to plan and implement an effective, comprehensive performance improvement system.
Pre-Conference Sessions Saturday, April 25, 2009

Saturday, April 25, 2009

Performance Improvement in Opioid Treatment (continued)

Module Four - Using Outcome Studies in PI Programs
The goal of this module is to discuss the benefits and challenges of examining existing outcome studies in the opioid treatment field and to explore how to develop clinic- or program-based OTP outcome studies.

Module Five - The 12 Steps of the Performance Improvement Process
The purpose of this module is to facilitate, review, and discuss the key elements of an effective performance improvement process. The module will also include strategies for addressing some of the challenges organizations encounter in PI programs including data collection and analysis, writing outcome measures, and evaluating plan effectiveness.

Module Six - Planning to Move Forward
The purpose of this session is to bring the participants together to review lessons learned during the training, to discuss how they will apply those lessons in their own organizations, and to develop specific action plans to address performance improvement needs in their organizations.

Module Seven - Workshop Closing Activities
This section of the workshop will include a summary of the day’s training, a review of participant expectations, and completion of participants’ workshop evaluation forms.

Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

3:00 PM - 5:00 PM Murray Hill B

The Physician Clinical Support System - Improving Office Based Care of Opioid Dependence

David Fiellin, MD, Yale University School of Medicine, New Haven, CT
Judith Martin, MD, The 14th Street Clinic, Oakland, CA
James Egan, MPH, The New York Academy of Medicine, New York, NY

Office-based treatment of opioid dependence with buprenorphine is a new practice in American medicine. Most U.S. physicians have not had extensive training nor the opportunity to provide this type of care. The federally mandated 8 hour courses that are required for physicians to prescribe buprenorphine, cover the treatment of opioid dependence but may leave questions unanswered. The Physician Clinical Support System (PCSS) is a federally funded program, administered by ASAM, in conjunction with AATOD, primary care, pain, psychiatric, HIV and other medical societies, that is designed to provide education and support for physicians who offer office-based treatment of opioid dependence with buprenorphine. This workshop will describe the current status of buprenorphine training and treatment in the U.S., describe the PCSS, its goals, make-up, services, and resources, including more than 3000 participants and 83 physician mentors who constitute the program. We will describe the specialized services including internet, email, telephone and on-site services that have been developed to improve the quality of care that is provided for opioid dependent patients. We will present data and describe PCSS resources on buprenorphine induction, counseling, buprenorphine dosing, payment and reimbursement, hepatitis, adherence, diversion and HIV - issues that confront physician practices as they begin to provide office-based care for opioid dependent patients.

Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

AATOD Open Board Meeting
Regent Parlor
Saturday, April 25, 2009 • 5:00PM – 8:45PM
**Pre-Conference Sessions**

**Sunday, April 26, 2009**

**8:00 AM - 5:30 PM**  
**Rendezvous Trianon**

**Opioid Maintenance Pharmacotherapy: A Course for Clinicians**

Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA

Susan Neshin, MD, JSAS HealthCare, Inc., Asbury Park, NJ

J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL

Trusandra Taylor, MD, NETSTEPS, ACT I AND II, Philadelphia, PA

This course is recommended for clinicians with experience and/or interest in medication assisted treatment of opioid dependence. This program provides basic and state of the art information. The curriculum is updated to include current consensus guidance for best practice treatment for opioid addiction. Topics include overview of opioid dependence, epidemiology, opioid pharmacology/neurobiology; evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone mortality, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management and an overview of buprenorphine.

Participants will receive a comprehensive syllabus with reference and resource materials. The curriculum will include relevant case study discussion with audience participation to facilitate the learning process. To further integrate the educational objectives, participants are encouraged to discuss challenging problems and clinical issues to facilitate understanding of didactic principles.

Four experienced opioid treatment medical directors will conduct the program, focusing on the goal for participants to acquire the essential knowledge and skills necessary to deliver safe and effective medication assisted treatment for patients with opioid dependence.

The $150.00 registration fee includes a morning coffee service, afternoon luncheon and the evening’s welcome reception. On-site registration can be done at the AATOD registration desk.

Sponsored by The American Association for the Treatment of Opioid Dependence, Inc. and American Society of Addiction Medicine in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the American Association for the Treatment of Opioid Dependence, Inc. and the National Institute on Drug Abuse.

---

**8:30 AM - 12:30 PM**  
**Nassau Suite**

**Countering Opioid Stigma: Communicating Messages to Influence Public Perception**

Frank J. Carillo, ECG, Inc., Englewood, NJ

Dan McGill, McGill Consulting, Brooklyn, NY

Opioid treatment programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately to operate in the best interests of our patients and communities.

This workshop teaches three key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication-assisted treatment (MAT). These messages resulted from a year-long pilot project entitled “Communicating Messages That Achieve Results”. Providers will hear these messages and learn how to communicate them in order to create a positive impact within their communities. The workshop will include Q & A techniques designed to deal with emotionally charged audiences while reinforcing the presenter’s objective.

This is an updated workshop that premiered at the 2006 Atlanta Conference and was repeated by popular demand in San Diego in 2007. MAT advocates using this approach have been very successful, hence another chance to experience this training!

Sponsored by The American Association for the Treatment of Opioid Dependence, Inc.

Supported by VistaPharm, Inc.
**PRE-CONFERENCE SESSIONS**

**Sunday, April 26, 2009**

**9:00 AM - 12:00 PM  Beekman Parlor & Sutton North**

**Opioid Treatment Program Accreditation - Town Hall Meeting**

*Megan Marx, MPA, The Joint Commission, Littleton, CO*

*Mary Cesare-Murphy, PhD, The Joint Commission, Oakbrook Terrace, IL*

This session is designed to be an open forum for Joint Commission accredited programs to discuss accreditation questions, concerns & challenges. Presenters will provide an overview of OTP accreditation to date. Topics expected to be covered include:

- Changes in the scoring & decision making process
- Changes in the CAMBHC – Leadership Chapter
- Robust Process Improvement

Presenters will split the two hour presentation time equally, allowing for Q&A throughout the presentation.

**Workshop Objectives**

At the end of this workshop participants will be able to:

1. Understand changes made in the scoring & accreditation decision making process & how they may affect their program.
2. Understand changes made in the CAMBHC Leadership chapter, & how to implement these changes in their program.
3. Discuss robust process improvement & identify where it may apply to their program.

Registration for this workshop is open to all Joint Commission Accredited Treatment Programs. To register on-site, please visit the Joint Commission Registration Desk.

Sponsored by The Joint Commission.

**9:00 AM - 5:30 PM  Sutton Center & South**

**State Opioid Treatment Authorities' Meeting (Closed Session for State and Federal Officials)**

*Robert Lubran, MS, Center for Substance Abuse Treatment, Rockville, MD*

*Nicholas Reuter, MPH, Center for Substance Abuse Treatment, Rockville, MD*

*Sara Azimi-Bolourian, Center for Substance Abuse Treatment, Rockville, MD*

*Mary Lou Ojeda, Center for Substance Abuse Treatment, Rockville, MD*

The Clinical Trials Network (CTN) is an important program of the National Institute on Drug Abuse (NIDA) focused on the design and implementation of clinically relevant studies in the field of drug addiction treatment research. It consists of sixteen geographically diverse “Nodes” centered in key academic institutions, partnering with local Community Treatment Programs (CTPs). Since 1999, CTN has served as NIDA’s primary vehicle for blending the interests of research and practice and improving drug abuse treatment through science. This includes the Prescription Opioid Addiction Treatment Study and other initiatives focused on prescription opioid addiction and chronic pain.

(Continued on page 8)
Many people with prescription opioid dependence have chronic pain, and there is also a substantial overlap with the use of heroin. The first presentation will focus on decisions that were made in order to define prescription opioid population in the Prescription Opioid Addiction Treatment Study, the largest and most comprehensive opioid analgesic dependence treatment study to be conducted so far, to produce a study population that was both distinct and new but also representative of patients seeking treatment in the community. Furthermore, the presentation will show previously unexamined characteristics of individuals presenting specifically for opioid analgesic dependence treatment.

The second presentation will highlight the issues facing substance abuse clinicians who are treating opioid dependent patients with chronic non-cancer pain. The presentation will review preliminary data from a treatment study designed to address pain and addiction concurrently, and will raise issues related to the use of methadone vs. buprenorphine vs. commonly abused opioid analgesics such as hydrocodone or oxycodone for treating co-occurring pain and opioid addiction.

The third presentation will describe recent information on how to assess and address aberrant drug taking behaviors during pain management. Furthermore, a detailed description of issues related to pain management in patients with opioid dependence and strategies for how to address this will be presented.

Supported by the National Institute on Drug Abuse and the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN).

This session will introduce OTP administrators to the key elements of a risk management program and how they can be directly applied to OTPs. Attendees will also get the most current information available about leading legal risks to OTP operations in addition to a discussion of some critical court cases that have recently affected OTPs. Topics to be covered include:

- **Risk management basics:**
  - What happens to the program when adverse events occur
  - Scope of risk management
  - Common risk identifiers
  - Setting priorities
  - Risk prevention and minimization
  - Claims management

- **Existing and emerging medical, clinical and legal standards of care for OTPs:**
  - The role that accreditation, certification, regulatory and clinical practice guidelines play in setting standards of care for OTPs
  - Recent negligence/malpractice lawsuits and related legal developments involving OTPs and their patients

- **Developing protective medical, clinical and legal strategies to deal with common legal and liability risks, including:**
  - Patient induction, dosing and monitoring issues
  - Impaired driving concerns
  - Assessing and addressing complex needs: patients with co-occurring disorders; continuing substance use; other complicating factors
  - OTPs’ liability for patients’ actions

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.

Supported by Substance Abuse Mental Health Services Administration, Center for Substance Abuse Treatment.

---

### Risk Management in the OTP

**Nassau Suite**

**1:00 PM - 4:00 PM**

*Catherine H. O’Neill, JD, Legal Action Center, New York, NY*

*Alan Wartenberg, MD, Tufts University, Boston MA; Opioid Treatment Program, Providence VA Medical Center; Providence, RI*

Health care risk management programs emerged 30 years ago and were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that opioid treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. Accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management.

### Hepatitis Education for Opioid Treatment Providers

**Regent Parlor**

**1:00 PM - 5:00 PM**

*Susan Simon, Hepatitis C Association, Scotch Plains, NJ*

*Bruce Burkett, Hepatitis C Association, Missouri Hepatitis C Alliance, Columbia, MO*

*Betsy Ingram-Diver, Hepatitis C Association, Lake Superior College, Duluth, MN*

*Patty Gilbert, Hepatitis C Association, Hampton-Newport News Community Services Board, Hampton, VA*

*David Fiellin, MD, Yale University School of Medicine, New Haven, CT*

*Jeanette Tetrault, MD, Yale University School of Medicine, New Haven, CT*
Hepatitis C Virus (HCV) is considered the most common blood-borne infection in the United States. There are approximately 5 million people infected. Injection drug use accounts for more than two-thirds of all new infections in the United States. OTPs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmissions.

This updated session will provide the most recent information on hepatitis A, B and C, diagnosis, transmission, risk factors, screening, diagnostic testing, referral, treatment, new drugs in trial, healthy behaviors, counseling issues and barriers to care.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.

Supported by Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

1:00 PM - 5:00 PM  Beekman Parlor & Sutton North
Trends and Changes in the Quality Framework called “Accreditation”
Bettye Harrison, CARF International, Tucson, AZ
Darren Lehrfeld, CARF International, Tucson, AZ

This session is designed to provide a discussion of the changes occurring in the framework of accreditation. Starting this year, CARF International has reorganized its standards into a model we hope will help CARF-accredited organizations to better meet the demands of the modern health and human services environment. The growing demands of the environment require opioid treatment programs to focus their time and resources on strategies to ensure quality service provision. The reorganization of the CARF Business Practice Standards into the ASPIRE to Excellence™ model demonstrates CARF’s continued commitment to assisting its accredited organization in navigating this changing environment.

The session will focus on:
- An overview of quality standards
- Trends in the provider environment and standard conformance
- Continuous improvement strategies to position organizations for continued success

Sponsored by the Commission on Accreditation of Rehabilitation Facilities (CARF).
**Exhibit and Poster Sessions**

**Sunday, April 26**  2:00PM – 5:00PM
- **P 101** For More Effective Treatment & Better Outcome  
  Mercedes Lovrecic, MD

**Monday, April 27**  7:30AM – 4:30PM
- **P 102** Cultural Factors Impacting Compliance of African Americans in Opioid Treatment Programs  
  Arthur L. Burnett, Sr., LL.B.

**Tuesday, April 28**  7:30AM – 1:30PM
- **P 104** Reproductive Recovery: The Mommies Program A Collaborative Relationship Between Choices Recovery Program Methadone Clinic and Luzerne County Children and Youth Parenting Center  
  Sandra Ancas, MSW
- **P 105** Post-Traumatic Stress Disorder and Substance Use Among Women in Methadone Maintenance Clinics: Screening, Staff Training and Treatment  
  Shabtay Levit, MSW
- **P 106** Accreditation Standards Improvement Initiative  
  Megan Marx, MPA
- **P 107** Recovery Focused Care: Medication Assisted Recovery is More Than Just Medication  
  Roland C. Lamb, MA
- **P 108** Starting Treatment with Agonist Replacement Therapy: The START Study: The Community Treatment Provider's Experience  
  Allan J. Cohen, MA

**P 109** Rapid Growth, Rapid Change: Growing High Integrity Programs through Effective Management and Vision  
  Brent Scobie, MSW

**P 110** Beyond Medication: Integrating Psychotherapies in OTP  
  Alexander Kantchelov, MD

**P 111** HIV Prevention Interventions Targeting the Problem of Engaging in Sex under the Influence of Drugs and Alcohol while in Substance Abuse Treatment  
  Donald Calsyn, PhD

**P 112** Comprehensive Methadone Treatment as HIV Prevention: Implementation and Scale-up of Methadone Treatment in Vietnam as a Government of Vietnam/PEPFAR Collaboration  
  Lynn Sullivan, MD

**P 113** Medication Assisted Recovery and Support: A 12 Step Fellowship Program for the Medication Assisted Patient in Recovery  
  Ralph "Bo" B. Waddell, III, AS

**P 114** OTP Treatment Experience Among Incarcerated Men in Puerto Rico  
  Begoña Rivera, PsyD

**P 115** Outcome Study of the Living Skills Recovery Curriculum with Opioid Dependent Mentally Ill Clients  
  Pat J. Precin, MS

**P 116** The Road Less Traveled: Client Utilization of a Methadone-to-Abstinence Residential (MTAR) Therapeutic Community Program in NY  
  Janetta Astone-Twerell, PhD

**P 117** Patient Safety In Opioid Addiction Treatment - A Survey of OTP Training in Pennsylvania  
  Trusandra E. Taylor, MD
Exhibit and Poster Sessions

**P 118** Boston's OTP Journey from 1972-2009  
*Paul E. Bowman, BA*

**P 119** Mortality Report Form  
*Alina Walizada, MS*

**P 120** The New Strategies of Harm Reduction Project on Drug Prevention in Taiwan  
*Jih-Chiao Chu*

**P 121** Survey Analyses for Implementing an Electronic Information System to Enhance Practice at an Opioid Treatment Program  
*Steven Kritz, MD*

**P 122** Katrina and Rita - Two + Years Later  
*Jane C. Maxwell, PhD*

**P 123** One Stop Shop Model of Treatment and Care Model for Street Drug Users  
*Bijan Nassirimanesh, MD*

**P 124** Gender Differences in Methadone Maintenance Treatment Outcome  
*Liljana A. Ignjatova, MD*

**P 125** Psychiatric and Substance Use Correlates of Physical Pain in Methadone Maintenance  
*Declan T. Barry, PhD*

**P 126** HAART Use in an Integrated Suboxone/HIV Primary Care Program  
*Helen G. Loewenthal, MSW*

**P 127** Smoking Cessation Program in a Methadone Maintenance Program  
*Lewis E. Galaway, MA*

**P 128** Work Matters: The Importance of Integrating Vocational Rehabilitation Services to Improve Treatment Outcomes  
*Michele Buoninfante, MA*

**P 129** Buprenorphine Maintenance in Jail and at Post-Release  
*Andrew Rosenblum, PhD*

**P 130** Buprenorphine: A Guide for Nurses  
*Sara Azimi-Bolourian, MSN*

**P 131** Opioid Addiction Treatment Modalities in Ukraine. Availability and Challenges  
*Nataliya Vlasova, MA*

**P 132** Former Heroin Addicts Currently in Methadone Maintenance Treatment (MMT) with Axis I & II Psychiatric Diagnosis Presented Best Cumulative Retention Compared to no Axis I and no Axis I & II Groups  
*Einat Peles, PhD*

**P 133** Observational Studies and Follow-Up of Patients in Treatment with Olanzapine and Substitutive Drug  
*Maria Chiara Pieri, MD*

*Please Note: Posters are not approved for CME credit.*
CONFERENCE OBJECTIVES
The goals and objectives of the 2009 American Association for the Treatment of Opioid Dependence, Inc. National conference are:
• Identify and provide to the target audience new information of critical concern to the field of treatment for opioid addiction
• Provide a forum for analyzing and evaluating the implications of new information
• Demonstrate and provide opportunities for participants to practice approaches and techniques for improving clinical services and administrative functioning.

CONFERENCE SESSIONS  Monday, April 27, 2009

opal plenary session
8:45AM – 10:15AM Grand Ballroom
Meeting Challenges In Turbulent Times: New York State’s Transformed Treatment System and Continuum of Care

Welcome and Introductions
Ira J. Marion, MA, Conference Chairperson, 2009 Director, Government Relations and Public Policy, Albert Einstein College of Medicine

The State of the Field: Meeting Challenges in Turbulent Times
Mark W. Parrino, President, American Association for the Treatment of Opioid Dependence, Inc.

Transforming Methadone Treatment in New York State
The Honorable Karen M. Carpenter-Palumbo, Commissioner, New York State Office of Alcoholism and Substance Abuse Services

The Opening Plenary will focus on the significant challenges facing our field. Conference Chairperson, Mr. Ira J. Marion, will open the conference by welcoming attendees to New York City and will provide an overview of the conference. Mr. Marion will also discuss the implications of the repeal of the Rockefeller Drug Law in New York State and its impact on increasing access to treatment for opioid dependent individuals. Mr. Mark Parrino, AATOD President, will present an overview of the challenges facing OTPs in the United States and AATOD’s initiatives to respond to these changing dynamics now and into the future. Conferees will hear from New York State’s Commissioner of Alcoholism and Substance Abuse Services, Karen M. Carpenter-Palumbo, whose energy and commitment will motivate all in attendance. Early in her tenure as Commissioner, Ms. Carpenter-Palumbo saw the need for a plan to transform New York’s OTP system, reforming regulations, taking OTPs out of the “silo,” and making them full partners in the prevention, treatment and recovery continuum in New York State, the largest system in the nation. Commissioner Carpenter-Palumbo will outline New York’s transformation plan for OTPs.

*Please Note: Session is not approved for CME from ASAM.

Workshop Sessions
10:30AM – 12:00PM
Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

Basic Track: This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend ALL six sessions listed will receive a special certificate of completion. Basic Track Workshop Sessions: A1, B1, C1, D1, E1 and F1

A1
Medical Issues for Counselors: Four Patient Questions About Methadone
Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

This workshop introduces the medical model of addiction, and reviews questions commonly asked by patients about the medication itself. Why is methadone better than using heroin? How do I know I'm taking the right dose? How long should I stay on methadone maintenance? What are the side effects of methadone? Counselors use this information in their therapeutic alliance with the patient who is enrolled in methadone maintenance.

* Note: Basic Track
**A2**  
**Nassau Suite**  
**How to Effectively Communicate Research and Policy Recommendations to Key Decision-Makers**  
Jenny Collier, JD, Independent Advocacy and Policy Consultant, Washington, DC  
Opioid-based treatment is one of the best-researched addiction treatments in the world, but policy makers continue to doubt its effectiveness. Such misunderstanding reduces funding for and stalls implementation of important opioid treatment policies. In this workshop, researchers, providers, and advocates will improve their ability to translate opioid treatment research and practice into concrete policy recommendations. Participants will gain tools to effectively communicate these recommendations to local, state, and federal decision-makers.

**A3**  
**Trianon Ballroom**  
**Staff Training and Program Implementation of an Evidence-Based Treatment for Co-Occurring PTSD in Community OTPs**  
Mark P. McGovern, PhD, Dartmouth Medical School, Lebanon, NH  
Phil F. Richmond, MS, Hartford Dispensary, Hartford, CT  
Aliza Castro, MSW, Hartford Dispensary, Hartford, CT  
This workshop describes the development and implementation of a simple, practical evidence-based practice, cognitive behavioral therapy, for patients in methadone maintenance, for one of the most vexing co-occurring psychiatric disorders: Posttraumatic Stress Disorder (PTSD). There will be a description of the outcomes of this project along with lessons learned, challenges and recommendations for implementation in other settings. New data, from a randomized controlled trial comparing the CBT with individual addiction counseling, will also be presented.

**A4**  
**Beekman Parlor & Sutton North**  
**From Conception to Postpartum: Update of Methadone During the Perinatal Period**  
John McCarthy, MD, Bi-Valley Medical Clinic, Sacramento, CA  
Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD  
Karol Kaltenbach, PhD, Thomas Jefferson University, Philadelphia, PA  
This workshop focuses on three issues. The first presentation reports on outcomes of neonates born to women who conceived and are maintained on methadone throughout pregnancy; the second reviews data supporting the current USA clinical guidelines regarding medication assisted withdrawal during pregnancy; and the third presents the results of a retrospective study tracking maternal dose at the beginning of the third trimester, changes across the third trimester, dose at delivery, and dose changes throughout six (6) weeks postpartum.

**A5**  
**Sutton Center & South**  
**Philadelphia Prison Experiment: 10 Years of MAT Within a Correctional Setting on a Limited Budget**  
John T Carroll, NCAC II / CCS, Northeast Treatment Centers, Philadelphia, PA  
Roland Lamb, MA, Philadelphia Department of Behavioral Health, Philadelphia, PA  
Over the past 10 years, an evolutionary collaboration has developed for the management of methadone maintained inmates incarcerated within the Philadelphia Prison System. The treatment model evolved from short term methadone detoxification into a state-of-the-art treatment program providing methadone maintenance to 400+ inmates a year with innovative re-entry services yielding extraordinary outcomes. The program design successfully incorporates the culture, factors and forces of a correctional environment to deliver comprehensive cost effective MAT.

---

THE POLICY MAKER’S LUNCHEON  
on Monday, April 27, 2009 is supported through a grant from Bendiner & Schlesinger, Inc.
1:30PM – 3:00PM Hot Topic Round Tables
Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

• Discharges for Financial Reasons
  Facilitators: Dana Moulton, CMA and Ron Jackson, MSW
  Gibson Suite

• Smoking Cessation in MAT
  Facilitator: Caroline Waterman
  Holland Suite

• Disaster Planning in OTPs
  Facilitator: Arlene Stanton, PhD
  Lincoln Suite

• OD Prevention in OTPs
  Facilitator: Randy Seewald, MD
  New York Suite

• Aging Issues
  Facilitator: Carolyn Drennan
  Midtown Suite

• Driving Safety
  Facilitator: Catherine H. O’Neill, JD
  Rendezvous Trianon

*Please Note: Hot Topic Sessions are not approved for CME by ASAM.

1:30PM – 3:00PM

#1 Beekman Parlor & Sutton North

Integrating Routine Domestic Violence Assessment and Intervention into Opioid Dependency Settings

Monica Joseph, PhD, Addiction Research and Treatment Corporation, New York, NY
Michelle Melendez, MSW, Addiction Research and Treatment Corporation, New York, NY
Melissa Mei-Yu Lin Chu, MS, Addiction and Research Treatment Corporation, New York, NY

This presentation will address the research findings related to the prevalence of substance abuse and domestic violence, as well as attitudes and perceptions of staff in opioid dependency programs and domestic violence settings. A current model for assessing domestic violence within substance abuse settings and substance abuse within domestic violence settings will be described. Concrete strategies for addressing the knowledge, attitudes/values and skills needed for corresponding interventions will be presented. Variables that should be integrated into developing a seamless resource network will also be examined.

#2 Sutton Center & South

Electronic Health Records and Opioid Treatment Programs

Nicholas P. Reuter, MPH, Substance Abuse and Mental Health Services Administration, CSAT, Rockville, MD
Mary Murphy, Veterans Affairs Hospital OTP, Washington, DC
David Picolli, Discovery House, Providence, RI

The use of electronic health recordkeeping will continue to expand in the coming years. This workshop will highlight two OTP systems that have complete electronic health records (EHR). A CSAT representative will discuss how EHRs align with Federal recordkeeping requirements. Participants will understand the challenges of establishing a system, together with the reimbursement and other advantages tied to EHRs.

Audiovisual support provided by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

#3 Nassau Suite

Methadone Maintenance and the Child Welfare System: What We Know and What We are Learning

Steve Hornberger, MSW, National Association for Children of Alcoholics, Silver Spring, MD
Patti Juliana, MSW, Beth Israel Medical Center, New York, NY
Naomi Weinstein, MPH, Center on Addiction and the Family, Phoenix House, New York, NY

This session will address developing collaborative relationships between the child welfare system and methadone programs, improving outcomes for families and increasing family involvement as a combined effort. Presenters will discuss a cross system training initiative in New York City, resources to help patients and family members and share one agency’s change process to partner with the child welfare system.

EXHIBITOR NETWORKING BREAK
Rhinelander Gallery
Monday, April 27, 2009 3:00PM – 4:00PM
Sponsored in part by O. Berk Kols Container Inc. and Tower Systems, Inc.
**Conference Sessions**

**Monday, April 27, 2009**

**4:00PM – 5:30PM Workshop Sessions**

**B1**

**Mercury Ballroom**

**Alcohol Abuse in Methadone Maintenance Patients: Understanding and Addressing a Serious Problem**

Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment (BAART), Sherman Oaks, CA

Adeline Nyamathi, PhD, UCLA School of Nursing, Los Angeles, CA

Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

This workshop presents the problem of alcohol abuse in agonist-maintained patients including a review of prevalence rates across populations with differing demographics as well as evidence-based outcome of treatment interventions. We will explore a variety of alcohol-related clinical issues faced by treatment providers and discuss how these issues are addressed in the OTP setting. A description of findings from an NIAAA-funded research study using motivational interviewing will be presented.

*Note: Basic Track*

**B2**

**Trianon Ballroom**

**Peer-to-Peer Recovery Services in MAT: Early Lessons from the MARS Project**

Joycelyn S. Woods, MA, National Alliance of Methadone Advocates (NAMA), New York, NY

Jo L. Sotheran, PhD, National Alliance of Methadone Advocates (NAMA), Brooklyn, NY

Howard S. Lotsof, BFA, National Alliance of Methadone Advocates, Dora Weiner Foundation, Staten Island, NY

Peer-to-peer recovery support services are in their infancy in MAT, although well established in other treatment modalities. The National Alliance of Methadone Advocates was awarded the first MAT project within CSAT’s Recovery Community Services Project. The Medication Assisted Recovery Services (MARS) project, with its central vision of a completely peer-based project, is now in its second year. This presentation will describe three aspects of the program, and how they have evolved since the program began, with particular attention to the effects of being embedded in MAT.

**B3**

**Beekman Parlor & Sutton South**

**Expansion of Buprenorphine Treatment for Opioid Dependence into Community Settings: A State-Funded Best Practice Model**

Colleen LaBelle, RN, Boston University Medical Center, Boston, MA

Hilary Jacobs, MSW, Bureau of Substance Abuse Services, MA Department of Public Health, Boston, MA

This workshop will highlight a best practice model that allowed for the expansion of buprenorphine treatment in Massachusetts providing training, technical support, and nurse care managers to 20 community sites with State funding. The model addressed barriers to treatment by providing clinical and technical support to physician providers in community settings. This innovative demonstration project has allowed for the expansion of opioid treatment into primary care practice setting while requiring integration with behavioral health care.

**B4**

**Sutton Center & South**

**Consideration of Cognitive Disabilities in the Treatment of Opioid Dependence**

Frank R. Sparadeo, PhD, Informed Interventions, LLC, East Greenwich, RI

Cognitive impairments can occur directly from substance abuse or from other causes such as developmental disability or traumatic brain injury. This workshop has been developed to introduce substance abuse counselors to the process of identifying and treating individuals with co-occurring cognitive disability and substance abuse. This workshop will review normal brain-behavior relationships, the impact of substance abuse on cognitive functioning, how to assess cognitive functioning, and treatment modifications for various types of cognitive impairments.

**B5**

**Nassau Suite**

**Increasing Treatment Retention to Improve Outcomes: Patients’ Perspectives**

Robert P. Schwartz, MD, Friends Research Institute, Baltimore, MD

Shannon G. Mitchell, PhD, Friends Research Institute, Baltimore, MD

Sharon Kelly, PhD, Friends Research Institute, Baltimore, MD

Through NIDA support, Friends Research Institute and its OTP partners are examining ways to prevent premature discharge. Insights from in-depth interviews of patients discharged from six OTPs; findings from a study of interim methadone treatment as an approach to enhance early treatment retention; and, data from a study of patient satisfaction will be presented. Specific recommendations will be made to increase patient retention through the use of patient perspectives.
CONFERENCE SESSIONS

Monday, April 27, 2009

6:00PM - 8:00PM   Beekman Parlor & Sutton North
TOWN HALL: A Continuing Community Discussion of How OTPS and the Treatment Community Can Work Together to Prepare for the Next “Service Discontinuity”

Arlene Stanton, PhD, Division for Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT) Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Walter Ginter, CMA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY
Henry Bartlett, BA, Committee of Methadone Program Administrators of New York State (COMPA), New York, NY

In the aftermath of 9-11, SAMHSA’s D-ATM project (“Digital Access to Medication”) was conceived as a technological approach to help ensure that OTPs could effectively and safely provide medication to patients who had been displaced from programs where they were normally enrolled. In 2002, SAMHSA/CSAT, working with COMPA and a Steering Committee representing a range of stakeholders, conducted a feasibility and planning study, followed by a smaller developmental study. This confirmed the need for a deliberately simple, web-based, centralized database containing only the information needed by an OTP to verify patients’ identity and to provide accurate and safe dosing. In 2005, SAMHSA provided funding to develop the infrastructure for and conduct a limited pilot-test of the system (now known as D-ATM) in 3-4 major metropolitan areas. The purpose of Phase III, recently launched, will be to pursue a national expansion of the system, which promises to provide an important tool for OTPs and a critical means to assure service continuity to patients in treatment for opioid dependence. (More background can be found at the D-ATM website, http://datm.samhsa.gov/.)

However, the events of 9-11, Katrina, and many large-and smaller-scale disasters that have followed since the last AATOD conference, have made OTP staff, administrators, and patients all too aware of the kinds of policy issues that can emerge in the wake of disaster, beyond the scope of D-ATM to address.

This Town Hall will begin with a brief overview and status report on D-ATM as Phase III commences, moving to an open discussion of the kinds of disaster preparedness issues that have been encountered in dealing with real-life situations, whether widespread disasters or more routine service disruptions. For instance, how have programs dealt with reimbursement issues or differences in dosing practices, when faced with unfamiliar patients from other programs?

Tuesday, April 28, 2009

7:30AM   Rhinelander Gallery
Continental Breakfast
Sponsored by Reckitt-Benckiser Pharmaceuticals, Inc.

MIDDLE PLENARY SESSION
8:45 AM - 10:15 AM   Grand Ballroom
Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes

Two Personal Stories of Recovery through Medication Assisted Treatment

Anthony Badger, Carolyn Visconte
Union, NJ Schenectady, NY

Medication Assisted Treatment is Recovery
William L. White, MA, Senior Research Consultant, Chestnut Health Systems, Bloomington, IL

Integrating Recovery Oriented Systems of Care into Medication Assisted Treatment
H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD

The theme of the Conference “Treatment and Recovery – People and Outcomes” is an effort to urge OTPs to renew their focus on the patients in their treatment programs in

These are complicated issues and it is hoped this Town Hall will provide one means to continue a dialogue among the many members of the treatment community toward identifying which issues still need attention and who best can address them. Representatives of CSAT and other federal and state agencies, members of the D-ATM Steering Committee, and program directors, patients and staff who have had experience in working with DATM or in dealing with disaster first-hand, are especially encouraged to attend.

Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
CONFERENCE SESSIONS Tuesday, April 28, 2009

Middle Plenary Continued from Page 16

new and more significant ways. Individualized treatment and a renewed focus on outcomes are critical for a recovery plan for each patient. Treatment is always about the people whose lives are changed in different ways and the way they integrate their recovery into the fabric of community life. The integration of MAT and ROSC provides the opportunity to all treatment and recovery providers to identify best practices and desired outcomes to enhance the quality of life for each patient. Renowned recovery pioneer, William L. White, will speak about the growth of the recovery movement this decade and how it has embraced medication-assisted treatment as part of the recovery community. Dr. H. Westley Clark will present the importance of recovery-oriented systems of care in the SAMHSA matrix and will discuss the important new CSAT publication, ROSC in MAT. Most significantly, two patients in long-term recovery through participation in medication-assisted treatment will put a face and voice to their recovery with their compelling and important stories.

Audiovisual support provided by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

10:30AM – 12:00PM Workshop Sessions

C1 Beekman Parlor & Sutton North

A Guide to Implement a More Recovery Oriented System of Care in Opiate Treatment Programs

Walter Ginter, Medication Assisted Recovery Support (MARS) Project; National Alliance of Methadone Advocates (NAMA), New York, NY

Lisa Mojer-Torres, JD, Faces and Voices of Recovery (FaVoR), Washington, DC

Shannon B. Tait, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD

In May 2008 CSAT convened a panel to create, “A Guide to Introduce and Implement a More Recovery Oriented System of Care in Opiate Treatment Programs”. CSAT’s charge to the panel stated that in this system, treatment is no more or less important than any other support. This workshop will introduce and explain what a recovery oriented system is, point out problems unique to OTP’s in implementing such a system, and suggest possible solutions.

*Note: Basic Track

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

C2 Sutton Center & South

Buprenorphine in the OTP: A Full Spectrum of Options

Heidi Shah, MD, Spectrum Health Systems, Westborough, MA

Kristin Nolan, MA, Spectrum Health Systems, Worcester, MA

This workshop will describe four different buprenorphine treatment plans currently being offered by Spectrum Health Systems through several OTP’s in Massachusetts. These plans include: 1) outpatient detoxification, 2) induction phase observed treatment with transfer to a community provider for maintenance, 3) observed daily dosing while awaiting transfer to a community provider for maintenance, and 4) maintenance treatment by prescription using a chronic disease model of care.

C3 Nassau Suite

Treatment of Opioid Dependence and ADHD/ADD with Methadone or Buprenorphine and Central Stimulants

Olof Blix, MD, County Hospital Ryhov, Jonkoping, Sweden

Peter Nilsson, County Hospital Ryhov, Jonkoping, Sweden

ADHD and ADD together with drug dependence is common. Data at our clinic indicate that 29% of MAT patients also have symptoms of adult ADD or ADHD. Most identified patients report improvements in every day functioning when a central stimulant is added to their daily methadone or high dose buprenorphine medication. Focus will be on diagnostic methods, evaluation, a formalized follow-up protocol, and the every day challenges in working with this long over-looked patient population.

C4 Trianon Ballroom

What to do about QT: Assessing and Reducing Cardiac Risk in the OTP

Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

Mori J. Krantz, MD, University of Colorado, Denver, CO

Barry Stimmel, MD, Mt. Sinai School of Medicine, New York, NY

Andrew Byrne, MD, Dependency Medicine, Redfern, New South Wales, Australia

Methadone is one of many medications that can cause Torsades, a rare cardiac arrhythmia. One in five maintenance patients might be at risk, and two percent are at high risk of this serious cardiac complication. This workshop presents the draft of the findings. Solicitation of comments from the audience will be part of CSAT’s Field Review process.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
CONFERENCE SESSIONS

Tuesday, April 28, 2009

C5  Mercury Ballroom
Outcomes Research: Getting Results that Mean Something
Erin Stevenson, MSW, University of Kentucky CDAR, Lexington, KY
Hilary Jacobs, MSW, MA, Department of Public Health Bureau of Substance Abuse Services, Boston, MA
Frederick Pottle, MPA, CRC Health Group Recovery Division, Carlsbad, CA
This panel offers different perspectives on outcomes data collection and dissemination for opioid replacement treatment populations. Kentucky’s Opiate Replacement Treatment Outcome Study, Massachusetts’ Methadone Treatment Quality Assurance System, and CRC Health Group’s outpatient clinic network will help answer: How to cost-effectively collect patient level data and get results? How to respond to NOMS and other State, local and Federal data requests? How to translate outcomes into usable products for clinicians, treatment centers and policy-makers?
Sponsored by Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

1:30PM – 3:00PM Workshop Sessions

D1  Mercury Ballroom
Integrating Treatment for Co-Occurring Disorders
Joan E. Zweben, PhD, East Bay Community Recovery Project; Oakland, CA; University of California, San Francisco, CA
This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the opioid treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate the patients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.
*Note Basic Track

D2  Nassau Suite
Developing & Integrating Peer Mentoring Services
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT
Kurt Kemmling, CT Chapter National Alliance Methadone Advocates; CT Chapter National Alliance Methadone Advocates, Norwalk, CT
This workshop will focus on the development, implementation, and integration of peer mentoring services within a methadone treatment program. Potential benefits relating to patient outcomes and staff utilization management will be discussed. The presenters will focus on providing information the workshop participants will need to replicate all or part of the initiative at their own programs. One key area of focus will be the development and implementation of a training curriculum for the peer mentors.

D3  Beekman Parlor & Sutton North
Genetics and Addiction: A Current and Future Perspective
Mary Jeanne Kreek, MD, The Rockefeller University Hospital, New York, NY
Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment, San Francisco, CA
Louise Haynes, MSW, Medical University of South Carolina, Columbia, SC
Epidemiologic research has shown that the relative risk of developing an addiction to a substance, following self-exposure, ranges from 30 – 60 percent. Over the past decade significant advances in molecular genetics have identified a variety of variants of specific genes some of which are directly related to processes known to be involved in addiction while others, which are less well understood, offer future discovery. Staff and patients of community opioid treatment programs can and will be involved in the future development of genetic research, this will lead to a better understanding of addiction and thus to more specific treatment approaches which will produce improved treatment outcomes. This session will describe some of the current and future genetics research on opioid addiction and its implications for the treatment community.

The International Luncheon on Tuesday, April 28, 2009 is supported through grants from Covidien-Mallinckrodt, David Szerlip & Associates, Inc. and Colonial Management, LP.

The Award Pre-Banquet Reception on Tuesday, April 28, 2009 is supported in part through a grant from Smart Software Solutions.
Evaluating Multiple Buprenorphine Treatment Approaches and Integration into an IOP

Robert M. Freeman, BS, The APT Foundation, New Haven, CT
Lynn M. Madden, MPA, The APT Foundation, New Haven, CT
Sam A. Ball, PhD, The APT Foundation; Yale University School of Medicine, New Haven, CT

The APT Foundation, located in New Haven, CT maintains an integrated system of buprenorphine treatment and maintenance services by offering three distinct levels of care including Physician-based practice; Physician-based practice in a traditional outpatient setting; and buprenorphine Maintenance integrated into an OTP. Our evaluation of each program consists of data obtained from the self-administered Basis-24; baseline admission data; patient retention; service level data; and finally patient urinalysis data. Through analysis of patient response in each setting, a system of matching patients to service level as well as the development of a Buprenorphine continuum of care will be discussed.

Removing Systems Barriers to Implement Evidence-Based Practices

Kim Johnson, PhD, NIATx- University of Wisconsin Madison, Madison, WI
Victor Capoccia, PhD, NIATx and Open Society, Madison, WI
Thomas McLellan, PhD, Treatment Research Institute, Philadelphia, PA

In 2006 the Robert Wood Johnson Foundation initiated the Advancing Recovery program intended to promote adoption of five evidence-based practices in the addiction treatment (wrap around services, continuing care, medication assisted treatment, screening and brief intervention, and psychosocial interventions). This workshop will describe that program, present case examples from four states of how the system changes implementation and what effect they had. A discussion of the program’s implications for implementing evidence-based practices will also be included.

Awards Program

Tuesday, April 28, 2009  7:00PM – 9:30PM  Grand Ballroom

Introduction to the Awards Program

Please join us for the centerpiece of our Conference, a moving tribute to those individuals who have been nominated and selected by their peers for extraordinary service in the opioid treatment community. These successful Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983. AATOD has been responsible for bestowing this honor since the first Regional Conference of 1984 in New York.

The Nyswander/Dole “Marie” Awards will be presented by Anita Townley

Anita Townley was one of the first women admitted to methadone maintenance treatment in the early days of the program. Anita worked at Rockefeller University with Drs. Dole and Nyswander. Anita worked as secretary and assistant to Dr. Marie Nyswander for twenty years. But even more than that, Anita was their close friend; she was a colleague and confidant to Dr. Nyswander and to Dr. Dole. She was part of their extended methadone maintenance family, their social and family life. Anita remained close to Dr. Dole until his recent death. Being at the center of the development and expansion of methadone throughout the US and the world, Anita was able to meet so many of the personalities and early Nyswander/Dole awardees. As a successful patient, methadone treatment made it possible for Anita to work, raise a family and allowed her to travel extensively throughout the world. Anita is now retired, has a son, Bob Townley, who is the CEO of a large youth center in Tribeca and has two wonderful grandchildren.
The 2009 American Association for the Treatment of Opioid Dependence National Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award:

**Robert K. Brooner, PhD**

Dr. Brooner has tirelessly and successfully served the medication-assisted treatment community in Maryland and elsewhere for more than 20 years. Some of the work that captured the committee’s enthusiasm includes: 1) the creation of an adaptive treatment approach for opioid dependence that rapidly adjusts the scope and intensity of services to sustain good clinical response from patients. The Joint Commission honored this work by naming him a 2007 winner of the Ernest Amory Codman Award for innovative treatments that improve quality-of-care and patient safety, and identified the treatment as a “gold standard” for medication assisted programs in the 21st century; 2) his development of a citywide treatment initiative that makes specialized services readily available to poor treatment responders in publicly-supported treatment programs in Baltimore that use methadone; and 3) despite considerable demands on his time, Robert continues to provide clinical care to patients and makes himself readily available as an advisor and mentor to many people and programs.

**Kim Comstock, MEd**

Kim Comstock M.Ed., a NTP sponsor since 1997, focuses primarily on community education, patient advocacy and empowerment, harm reduction and progressive program implementation. Her efforts include teaching methadone awareness (St. Edwards University and Institute for Chemical Dependency Studies), co-founding Texas Opioid Treatment Alliance, authoring articles advocating MAT for Recovery Today Newspaper, facilitating Texas CPS policy changes to support OTP patients and creating the first PAG (patient advocacy group) in Texas. Kim’s programs train interns from local schools and universities. She donates thousands of dollars per year to the clinic’s PAG to help patients with fees/financial hardships. She welcomes needle exchange to operate at the clinics. Her programs offer free acupuncture, yoga, a space for MA groups and financial incentives encouraging patients and their families to participate in services. Kim has always placed the interests of her patients as primary in all of her work.

**Peter Coleman, MS**

Throughout his career, Peter has been an advocate for moving the opioid treatment system in New York State towards a more patient-centered, evidenced-based approach. Peter has advocated for the provision of comprehensive and co-located services consistent with the chronic disease model of care. In the best traditions of Marie Nyswander and Vincent Dole, Peter believes in listening to patients and insists that our treatment approach must always be respectful of patients’ rights, human dignity, and self-determination. Peter has worked towards these goals in his former position at Staten Island University Hospital as well as in the many opioid treatment clinics operated by the New York City Health and Hospitals Corporation. Peter is a leader in our field in New York. He generously shares his time, expertise, and wisdom with others through his work on the COMPA Board and the New York State Governor’s Advisory Committee for Alcoholism and Substance Abuse Treatment. Most recently Peter has been an active member of the OASAS Methadone Transformation Advisory Workgroup (MTAG) which seeks to mainstream medication assisted treatment throughout the large addiction treatment system in New York. Peter’s principled yet practical voice has been a major force in helping to develop a better OTP treatment system in our state.

**Mercedes Lovrecic, MD**

Mercedes Lovrecic MD, MSc – Slovenia (EU) has been a lecturer and practicing clinician in a methadone clinic in Slovenia since 1996. In 2002, with the support of European colleagues she co-founded the first outpatient clinic in Izola, Slovenia for the treatment of addiction and psychiatric comorbidity. In 2002, she received the “Chimera Award” in Oslo for her contribution to the development of effective opioid treatment in Europe. She also works at the National Institute of Public Health for the Republic of Slovenia and has served as a member of the Steering Group for the European Union Action Plan on Drugs. Mercedes is widely published and has frequently presented at EUROPAD and AAODT conferences.

**Judith Martin, MD**

In her 22 years in the addiction treatment field, Dr. Martin has assumed significant leadership roles in providing top quality treatment in a supportive and respectful manner. She is active as a physician working with patients, a teacher, a member of numerous expert committees, chair of important committees, and currently, President of the California Society of Addiction Medicine. Dr. Martin is appreciated for her warmth, intelligence, and graceful leadership style. She is highly knowledgeable, and able to communicate with a wide range of people in a manner that promotes finding common ground. Beginning counselors are enthusiastic about her ability to talk from their perspective, putting medical issues in understandable form. Advanced professionals appreciate her knowledge of the research literature and ability to describe complex issues succinctly. These qualities are evident in her work on many export work groups, her participation in research, and her publications.
### Gloria J. Mouzon, MD  Illinois

Through her work as a practitioner at several facilities and on statewide committees over the past 25 years, Dr. Mouzon has made meaningful and consistent contributions that have had significant impact on opioid treatment in Illinois. Due to the high quality of her work and her commitment to patients, Dr. Mouzon has earned the respect of the State Methadone Authority and colleagues throughout Illinois. Patients, regulating authorities, and program staff all rank Dr. Mouzon as an outstanding physician. Dr. Mouzon is highly skilled, demonstrating sound clinical judgment in working with patients with diverse needs. Her warm and open style helps to foster teamwork between nurses, counselors and patients. Dr. Mouzon has an amazing spirit. She approaches her work with honesty and integrity, and holds a deep respect for patients and their right to self-determination. As a physician, Dr. Mouzon has raised the bar for patient care.

### Raymond M. Pomm, MD  Florida

Dr. Pomm has worked in addiction treatment over 20 years and holds medical licenses in both Florida and Virginia. He is the Medical Director for River Region Human Services in Jacksonville, Florida. He is also the Medical Director for the Practitioners Program of Florida. He developed the first dual diagnosis program for methadone patients with serious psychiatric disorders in 1994 and has continued to set the standard for dual diagnosis care for this population. Dr. Pomm has also worked tirelessly with Family Practice physicians to enhance their understanding and treatment of substance use disorders, but particularly to the issues related to opiate addiction. He has championed the needs of impaired healthcare professionals in order to support their recovery and return to the workforce, including professionals on methadone and/or Suboxone. Dr. Pomm represents opiate addiction treatment services on several committees and workgroups at the state level.

### Deborah Powers, BS  Wisconsin

Ms. Powers is a tireless State Methadone Authority. Frequently she is at the office on weekends and available on her scheduled days off to resolve patient care issues. She is always willing to share her knowledge of pharmacology during patient staffings, especially drug interactions for pregnant women and the fetal impact. She has even provided clinical consultation to the Chief Medical Officers within the Department on the issue of drug interactions. Medication-assisted treatment remains one of the most stigmatized modalities in the treatment for substance use disorders and controversy surrounds it to this day. Deb has done a tremendous job to reduce the stigma and increase awareness around methadone maintenance. She has reminded all of us that treatment professionals remain leaders in the field of stigma reduction by conveying the understanding of the neuroscience of addiction, treatment effectiveness, and to act in the best interest of our patients for timely coordination of care.

### Alan Wartenberg, MD  Rhode Island

Dr. Wartenberg is the former Medical Director of the Addiction Recovery Program at Faulkner Hospital, and recently retired as the Corporate Medical Director of Discovery House Programs. He is the Associate Medical Director for the Providence VA Opioid Treatment Program and on the faculty of Tufts University School of Medicine. He is a fellow of the American Society of Addiction Medicine and the American College of Physicians specializing in medical management of addiction problems, including detoxification, and addiction psychopharmacology focusing on opioid treatment, including methadone and buprenorphine. He is a respected author and teacher in these areas. He has advocated for patients in need of treatment to have easy access and is passionate about providing excellent care to his patients.

### Friend of the Field Award

Presented by Mark W. Parrino, MPA

President American Association for the Treatment of Opioid Dependence, Inc.

The prestigious Friend of the Field Award was established by the American Association for the Treatment of Opioid Dependence, Inc. Board of Directors. This award recognizes extraordinary contributions to the field of opioid treatment by an individual or institution whose work, although not directly related to opioid treatment, has had a significant impact on our field. The 2009 Friend of the Field Award has been awarded to:

### A. Thomas McLellan, PhD

Dr. McLellan, CEO of the Treatment Research Institute, is perhaps best known for his pioneering introduction of the Addiction Severity Index and Treatment Services Review in the 1980s. Dr. McLellan later conceptualized data-driven measurement of treatment effectiveness, performance-based monitoring, and analysis of the nation’s substance abuse treatment system. Through his research and extensive knowledge of substance abuse treatment systems, Dr. McLellan has become a persuasive proponent of the view that addiction is a chronically relapsing condition, one that must be continually monitored and managed. Dr. McLellan has published more than 400 articles and chapters on addiction research and serves as Editor-in-Chief of the Journal of Substance Abuse Treatment. He is also an advisor to numerous government and nonprofit scientific organizations, including the Office of National Drug Control Policy, Research and Evaluation; the National Practice Laboratory of the American Psychiatric Association, the Swiss National Science Foundation, the World Health Organization, and the Greek government.
Richard Lane / Robert Holden Patient Advocacy Award
Presented by Jocelyn Woods, MA & Anthony Scro
Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike. Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of the American Association for the Treatment of Opioid Dependence, succeeding Richard Lane’s term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Walter Ginter, CMA
Mr. Ginter is the Project Director of NAMA’s Medication Assisted Recovery Service (M.A.R.S.) Project. He currently serves as national recovery advocacy and an At Large Director of Faces and Voices of Recovery (FaVoR), as a National Recovery Month Planning Partner, Chair of the Expert Panel creating a Guide to Implement a Recovery Oriented System of Care in OTP’s, and on the steering committee of the Digital Access to Medication (DATM) emergency database project. In NYS, he serves on the Methadone Transformation Advisory Group (MTAG) as Chair of the Recovery Committee and on the Commissioners Recovery Implementation Team (RIT). Walter has represented patients on more than 30 state and federal committees and panels and is responsible for creating NAMA’s Certified Methadone Advocate Training program. He is an extraordinary advocate who has raised awareness among patients, treatment providers and regulatory authorities. He has had a profound and positive effect on improving patient advocacy throughout the nation.

The 2009 Awards Banquet is supported through a grant from Covidien-Mallinckrodt.

CONFERENCE SESSIONS

Wednesday, April 29, 2009

7:00AM
Continental Breakfast
2nd Floor Promenade
Sponsored by VistaPharm, Inc.

8:00AM – 9:30AM
Workshop Sessions
E1
Mercury Ballroom
Focus on the Therapeutic Relationship
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT
Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This “basic track” workshop will focus on the essential fundamental counseling skill of forming and maintaining the therapeutic relationship. The presenter will help the participants assess their current core counseling skill set and provide an overview of the counseling techniques used to form and maintain the therapeutic relationship.

*Note Basic Track
**E3  Sutton Center & South**  
**Housing the Homeless Methadone Patient**  
_Herman Joseph, PhD, Retired Research Scientist, New York, NY_  
_Sam Tsemberis, PhD, Pathways to Housing, New York, NY_  
_William Panepinto, MSW, NYS Office of Alcohol & Substance Abuse Services, Albany, NY_  

Many homeless methadone patients have a range of co-occurring mental disorders and histories of arrests and incarceration. They face a unique stigma which limits their acceptance into programs and services. Pathways to Housing has targeted a housing-first program for this group and the majority of patients have responded positively to services offered. NYS QASAS, cognizant of the issues facing service provision for homeless methadone patients, has developed plans to address this issue which will be presented during this workshop.

**E4  Trianon Ballroom**  
**Methadone Mortality Update**  
_Jane C. Maxwell, PhD, University of Texas at Austin, Austin, TX_  
_Bruce Goldberger, PhD, University of Florida College of Medicine, Gainesville, FL_  
_Robert Lubran, MA, Center for Substance Abuse Treatment; Substance Abuse and Mental Health Services Administration, Rockville, MD_  

This session will review current data on methadone-associated deaths and the extent such deaths might be related to clinical practices of programs to which, as well as strategies to improve the quality of reporting, including uniform nomenclature, case definitions, and standards for toxicological testing to encourage uniform reporting. It will also discuss the latest actions by authorities to address the problem through improved data collection and training health care professionals in the management of pain and addiction.  

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

**E5  Nassau Suite**  
**The Matrix Model for Medication-Assisted Treatment**  
_Michael J. McCann, MA, Matrix Institute on Addictions, Los Angeles, CA_  
_Daniel George, MPH, Matrix Institute on Addictions, Los Angeles, CA_  

The Matrix Model Intensive Outpatient Treatment has been widely disseminated nationally and internationally. A growing number of providers of medication-assisted treatment have requested similar training and, in order to accommodate this need, the Matrix Institute has developed the Matrix Model Outpatient Program for Medication-assisted Treatment. This workshop will describe the core elements of the Matrix Model, address the special issues relevant to this patient population, and describe the program for medication-assisted treatment.

**9:45AM – 11:15AM**  
**Workshop Sessions**  
**F1  Mercury Ballroom**  
**One Year Later: Lessons Learned in the Implementation of Maryland’s Four Jail-Based OTP’s**  
_Greg Warren, MA, Maryland Department of Public Safety and Correctional Services, Baltimore, MD_  
_Akin Ayeni, MD, Correctional Medical Services, Inc., Baltimore, MD_  

The workshop will describe the challenges of implementing an OTP within a large and busy city jail, as well as how to forge linkages between institutional and clinical staff and with community OTPs. One year outcome data will be shared and its lessons learned- implications on clinical processes as well as its effect on the public health treatment system in Baltimore City.  

*Note: Basic Track*

**F2  Beekman Parlor & Sutton North**  
**Expanding and Improving the Health Responses to Drug and Alcohol Addiction: The National Advocacy Campaign**  
_Paul Samuels, JD, Legal Action Center, New York, NY_  
_Gabrielle de la Gueronniere, JD, Legal Action Center, Washington, DC_  

This workshop session will focus on an upcoming national campaign to expand and improve the health responses to drug and alcohol addiction, and to eliminate discrimination against people in recovery. This session will highlight the campaign’s focus on expanding access to medication-assisted treatment and eliminating policies that discriminate against people with opioid addiction histories. The presentation will include discussion of messaging and outreach strategies, and an update on federal and state policy matters.
**CONFERENCE SESSIONS**  
**Wednesday, April 29, 2009**

**F3  Sutton Center & South**

“Leave No Man Behind:” Clinical Considerations for Working with Veterans in Addictions Treatment

Carol Davidson, LCSW, Samaritan Village Veterans Program, New York, NY

Military service is a significant and transformative life experience that influences personal development throughout the life span of our veterans. This workshop will describe essential elements of the clinical culture, core treatment principles, and specialized services for combat-related PTSD that are offered in an addictions treatment program for veterans.

**F4  Trianon Ballroom**

Methadone Dose Reductions in Response to Benzodiazepine Abuse/Dependence: An Evaluation of a New Clinic Protocol

Janet G. Morgan, RN, Addiction Research and Treatment Services, Denver, CO  
Denise E. Vincioni, MA, Addiction Research and Treatment Services, Aurora, CO

This presentation will examine the impact of a protocol of reducing methadone dose levels for patients testing positive for unapproved benzodiazepine use or for overt benzodiazepine impairment. Data will be presented on illicit opiate use, retention, and increase in other drug or alcohol use, as well as accidental multi-drug overdoses before and after implementation of policy; the benefits of the policy for safety, against the possible decrease in the efficacy of MAT will be discussed.

**F5  Nassau Suite**

Methadone Transformation in New York State – Process and Outcomes

Frank McCorry, PhD, NYS Office of Alcohol & Substance Abuse Services, New York, NY  
Henry Bartlett, Committee of Methadone Program Administrators of New York State (COMPA), New York, NY  
Belinda Greenfield, MA, NYS Office of Alcohol & Substance Abuse Services, New York, NY

New York State stakeholders, including opioid treatment providers, coalition and advocacy groups, in conjunction with the state chemical dependency agency, have begun a journey towards transforming the state’s opioid treatment system. The concepts that are driving transformation, the linkages with other inter-/intra-agency workgroups, and fiscal reform efforts impact these efforts will be discussed. The products and implementation strategies of methadone transformation will be presented from the state, provider and patient perspective.

**CLOSING PLENARY SESSION**  
11:30AM – 12:45PM  
**Grand Ballroom**

**Policy, Programs and People**

Robert B. Millman, MD, Saul P. Steinberg Distinguished Professor of Psychiatry and Public Health, Weill Medical College, Cornell University and Director of the Drug and Alcohol Abuse Treatment and Research Service at the New York Hospital/ Columbia Presbyterian Medical Center

Mathea Falco, Esq., President of Drug Strategies, a non-profit research institute in Washington, D.C. promoting more effective approaches to the nation’s drug problems and former Assistant Secretary of State for International Narcotics Matters during the Carter Administration

Edward H. Jurith, Acting Director, Office of National Drug Control Policy, Executive Office of the President

Our Special Closing Plenary will unite the voices and themes of AATOD 2009. Participants will gain an unique understanding of public policy and system change, treatment programs into the future and the importance of our patients and their needs. Mathea Falco and Robert Millman will bring new perspectives, insights and voices that shape change to our conference. Chaired by Dr. Millman, our speakers will provide focus and direction to our public policy agenda, our programs and the treatment we provide. Edward Jurith will discuss the importance of effective treatment programs that are based in solid research and science. As we return to our homes and workplaces, this closing plenary will emphasize our core mission, our patients and those who still need our help.

---

**Join AATOD Today!**

www.aatod.org
Welcome to New York City
The Hospitality Committee is ready to roll out
The AATOD Stimulus Package

Start by relaxing at The Spa at Mandarin Oriental walking distance from our Host Hotel, Columbus Circle at 60th street, knock 25% off any hour or more treatment booked Monday through Wednesday by mentioning the TONY special.

Excite your mind with a simple call to 212-833-5414 to reserve FREE tickets to The Sony Wonder Technology Lab, Madison Avenue at 56th street, this four-story; interactive technology and entertainment museum is for all ages.

Indulge your taste buds for lunch or dinner at the New York Thai Grill & Sushi Bar, 54th Street between 5th and 6th Avenues, where sushi and non-sushi eaters alike can enjoy an eclectic menu of Asian delights with something for everyone at the All-U-Can-Eat price of $25.00. The steamed vegetable dumplings and Mango Chicken are menu favorites.

Of course no New York City trip would be complete without a night of Discounted Entertainment. The newly remodeled TKTS Booth at 47th and Broadway (Duffy Square) offers half price tickets to most of the Broadway and Off Broadway wonders. Ok last year’s TONY winner In the Heights and Long running smash Wicked won’t be on the boards at TKTS but come by the Hospitality booth and we will let you in on the little known secret to Discounted tickets to these Hot shows.

To learn more about these and other discounts available, feel free to visit the Hospitality Committee booth or speak with the NYC & Company volunteers located in the Registration Area. For those interested in seeing some of New York City’s Opioid Treatment Programs first hand, you can sign up to participate in our Clinic Tours on Wednesday.

Once again, Welcome to New York City. We look forward to guiding your personal stimulus package.

Cost-consciously submitted by Haynes, the 2009 AATOD Hospitality Chair.
Conference Notes

• Smoking is prohibited at all conference events.

• Your conference badge is your admission to all events and educational sessions. Please be sure to wear your badge to all conference functions.

• Participation in this conference assumes knowledge and authorization of audio and / or video recordings of portions of this conference.

• Part of the proceeds of the sleeping room rates will be used to defray conference expenses.

• Please take the time to complete all evaluation forms. Your feedback is extremely important to the presenters and AATOD.

Audio Taping Information

Don’t Miss A Single Important Word!

As a special service to attendees, the presentations will be available on Audio CD.

With scheduling conflicts and concurrent sessions, job Conference will make it possible to attend every important session via audio CD, using advanced techniques assuring the highest quality recordings.

High-speed duplication equipment eliminates long delays, allowing you to hear the important information shortly after each session has concluded. The CDs provide an excellent recap and a valuable training tool to those who could not attend.

Look for the Job Conference order desk located on the 2nd Floor Promenade area and take your information home with you, or place an order through the mail after the conference. Please refer to your registration packet for a complete listing of available sessions.

A Special Note for the Disabled

The American Association for the Treatment of Opioid Dependence, Inc. has taken steps required to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services, as outlined in the Americans with Disabilities Act.

Continuing Medical Education (CME) / Continuing Education Hours (CEHs)

The 2009 AATOD National Conference will award Continuing Medical Education (CME) and Continuing Education Hours (CEHs). Please see the back cover for specific information.

To apply for CMEs / CEHs, conference attendees must pay the associated fee, either in advance or at the on-site conference registration desk. Attendance at conference events will be verified electronically. Each attendee seeking CMEs / CEHs will have a bar code attached to his/her conference badge. At the end of EACH approved session, attendees must have the bar codes on their badges “scanned” by room monitors in order to record CME / CEH. These monitors will have electronic equipment that will automatically record each individual’s attendance in a database. The database will track and tabulate each attendee’s CMEs / CEHs. After the conference, certificates documenting attendance and the number of CMEs / CEHs earned will be electronically generated and mailed to all eligible attendees.

Attendees participating in ALL six Basic Track workshops will receive an additional certificate documenting their participation in this special training series.

Questions about CMEs / CEHs can be answered by staff at the Conference CME / CEH Desk located in the registration area.

Job Conference
Phone: 1-888-609-TAPE
Email: Job_CRS@att.net

New York City Information Is Located At The Hospitality Booth In The Registration Area.
EXHIBITOR DIRECTORY

The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation.

Addiction Professional
149th Avenue
New York, NY 10010
Phone/Fax: 212-812-4674; 212-228-1308
rbenenvent@vendomegrp.com
Addiction Professional is the addiction field’s essential guide to what is working in treatment and prevention and how clinicians can use this knowledge to achieve excellence in services.

Addiction Technology Transfer Center-National Office
5100 Rockhill Road
Kansas City, MO 64110
Phone/Fax: 816-235-6888; 816-235-6580
christyc@umkc.edu • www.ATTCnetwork.org
As a nationwide, multidisciplinary resource for professionals in the addictions treatment and recovery services field, the ATTC Network serves to: Raise awareness of evidence-based and promising treatment and recovery practices, Build skills to prepare the workforce to deliver state-of-the-art addictions treatment and recovery services, and Change practice by incorporating these new skills into everyday use for the purpose of improving addictions treatment and recovery outcomes.

Addiction Treatment Providers Insurance Program
555 North Lane, Suite 6060
Conshohocken, PA 19428
Phone/Fax: 610-941-9877; 610-941-9889
rjwillett@nsminc.com • www.addictiontreatmentproviders.com
The Addiction Treatment Providers Insurance Program is an exclusive program for the Addiction Treatment and Behavioral Health Treatment Industry. ATP offers coverage to meet the unique needs of all addiction & mental health treatment facilities and services a wide range of residential and outpatient treatment facilities and psychiatric & mental health clinics.

AIT Laboratories
2265 Executive Drive
Indianapolis, IN 46241
Phone/Fax: 800-875-3894; 317-243-2789
info@AITLabs.com • www.AITLabs.com
AIT Laboratories offers state-of-the-art analyses for pain management and clinical clients nationwide. Based in Indianapolis, AIT’s services include access to on-site board-certified toxicologists, instant-cup testing to identify drug misuse in new patients, a comprehensive urinalysis to monitor compliance, and immediate access to results via online reporting at www.AITLabs.com.

American Association for the Treatment of Opioid Dependence, Inc. (AATOD)
225 Varick Street, 4th floor
New York, NY 10014
Phone/Fax: 212-566-5554; 212-366-4647
info@aatod.org • www.aatod.org
The American Association for the Treatment of Opioid Dependence, Inc. (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive opioid treatment services throughout the United States. AATOD works with federal agencies, state substance abuse authorities and agencies within the criminal justice system concerning opioid treatment policy in addition to coordinating activities with advocacy groups and treatment providers in all regions of the country. AATOD continues to work on behalf of all its members by expanding access to quality addiction treatment services.

Ammon Analytical Laboratory, LLC
1622 South Wood Avenue
Linden, NJ 07036
Phone/Fax: 908-862-4404; 908-862-0605
nreyes@ammontox.com • www.ammontox.com
Ammon Analytical is a specialty state-of-the-art toxicology laboratory. Our niche market is dedicated to providing excellent service to those clinics seeking treatment for the opioid dependent community. Our facilities include sophisticated instruments and computer management systems that empower us with an efficient means to handle all of our client needs.

Anthony C. Baker Architects & Planners, P.C.
39 South Main Street Freeport
New York, NY 11520
Phone/Fax: 212-947-5818; 516-632-9748
acb@acb-architects.com • www.acb-architects.com
ACB Architects and Planners P.C. are established Architectural Design professionals in The Health Care field and specialize in services for OPIOID dependent clientele and the associations who provide its treatment. Built work includes clients like: Einstein College of Medicine, St. Vincent’s / Catholic Medical Centers, Beth Israel, & St. Mary's Hospital.

ASI-MV Connect
320 Needham Street, Suite 100
Newton, MA 02246
Phone/Fax: 617-332-6028; 617-332-1820
smehringer@inflexxion.com • www.asi-mvconnect.com
The Addiction Severity Index-Multimedia Version® Connect system is a powerful web-enabled version of ASI-MV that moves substance abuse assessment, treatment planning and data management to new heights. The system includes the client self-administered interview, clinical reports, and the ASI-MV Connect Data Center to simplify data gathering and analysis.

Bendiner & Schlesinger
140 58th Street, Suite 8D
Brooklyn, NY 11220
Phone/Fax: 212-353-5111; 212-598-0907
info@bendinerlab.com • www.bendinerlab.com
Bendiner & Schlesinger, Inc., a full-service laboratory, has more than 40 years experience in meeting the testing needs of treatment programs for opioid dependence throughout the U.S. Bendiner & Schlesinger, Inc. offers laboratory-based urine and oral-fluid drug screening, including complete differentiation and quantitation of positive screens of either specimen type.

Beth Israel Medical Center
221 N. Erie Street
New York, NY 10038
Phone: 212-420-2230
smquerk@chpnet.org • www.BethIsraelNY.org
For more than 40 years, Beth Israel Medical Center has operated the largest non-profit MMTP in the U.S. with 17 clinics throughout Manhattan and Brooklyn. Methadone has proven an invaluable tool for effective treatment and rehabilitation of opioid-addicted individuals. Our team works together to help patients eliminate opioid addiction and become self reliant.

Brown Consulting, Ltd.
121 N. Erie Street
Toledo, OH 43604
Phone/Fax: 800-495-6786; 419-241-8689
rwilhight@danbrownconsulting.com • www.danbrownconsulting.com
Since 1987, Brown Consulting, Ltd. has provided a full range of Research, Management Regulatory Compliance and Consulting Services for more than four hundred (400) organizations across thirty-eight (38) states. Today, Brown Consulting, Ltd. has established national recognition as a leader among Behavioral Services Consulting Organizations. Contact us at 800-495-6786.
**EXHIBITOR DIRECTORY**

**C & C Containers, LLC** Booth #231
2601 Lado Road
Albany, GA 31707
Ph/Fax: 229-869-6071; 229-903-0025
astone@cccontainers.net • www.cccontainers.net

C&C Containers is your medication bottle solutions company; specializing in providing affordable take-home bottles and child proof caps to Medication Assisted Treatment programs.

**CARF International** Booth #221
4891 East Grant Road
Tucson, AZ 85712
Ph/Fax: 520-325-1044; 520-318-1129
bharrison@carf.org • www.carf.org

Established in 1966 as the Commission on Accreditation of Rehabilitation Facilities, CARF International is an independent, nonprofit, accreditor of human service providers. CARF serves as a catalyst for improving the quality of life of the persons served by CARF-accredited organizations and the programs and services they provide. Please come by our booth or visit us online at www.carf.org.

**Clinical Science Laboratory, Inc.** Booth #321
51 Francis Avenue
Mansfield, MA 02048
Ph/Fax: 508-235-6106; 508-339-3540
don@clinicalsciencelab.com • www.clinicalsciencelab.com

Clinical Science Laboratory is the premier toxicology laboratory for the testing needs of opioid addiction treatment facilities. We tailor drug screens, both urine and oral fluid, to meet your testing requirements, and do all clinical blood testing in-house. Our trademark is “Personalized Service With Professional Commitment Since 1974.”

**Council on Accreditation** Booth #213
120 Wall Street
New York, NY 10005
Ph/Fax: 212-797-3000; 212-797-1428
dwood@coanet.org • www.coanet.org

Founded in 1977, the Council on Accreditation (COA) is an independent not-for-profit accreditor of the full continuum of community-based behavioral health care and social service organizations in the United States and Canada, and is one of the three leading accreditors of such service providers. Originally known as an accrediting body for family and children’s agencies, COA currently accredits 44 different service areas and over 70 types of programs. Over 1800 organizations – voluntary, public and proprietary, local and statewide, large and small have either successfully achieved COA accreditation or are currently engaged in the process.

**Coviden-Mallinkrodt** Booth #216
675 McDonnell Blvd.
St. Louis, MO 63042
Ph/Fax: 314-654-7128
Robert.lesnak@coviden.com • www.mallinkkrodt.com

Coviden-Mallinkrodt manufactures a complete line of Methadone products including Powders, Oral Concentrates (cherry flavored and sugar-free), and Dispersible tablets, unflavored and orange flavored. Mallinkrodt continues to support the field of addiction treatment with the AT Forum and ATF Website, ForumFax, patient education brochures and a series of training modules for clinicians.

**Emerging Solutions in Pain** Booth #328
101 Washington Street
Morrisville, PA 19067
Ph/Fax: 215-337-0956; 215-337-0959
www.emergingsolutionsinpain.com

Emerging Solutions in Pain is a non-branded disease awareness initiative focused on chronic pain management and the issues of abuse, misuse, and addiction of opioids. Our diverse array of resources were developed to assist clinicians in overcoming the challenges they face when treating patients with pain. Today’s source for tomorrow’s pain management.

**Friends Medical Laboratory** Booth #232
5820 Southwestern Blvd.
Baltimore, MD 21227
Ph/Fax: 410-247-4417; 410-247-4426
artdsgmn@aol.com • www.friendslab.com

Friends Medical Laboratory (FML) is a toxicology laboratory that has been performing drug testing since 1963. In 1968 FML began testing for methadone programs. FML offers a wide range of testing for drugs of abuse. They can test urine and oral fluid samples as well as offer confirmations of any pre-screening instant kits. FML has recently begun offering point of care or instant drug testing kits for both urine and oral fluids. Moreover, FML has begun offering testing to Pain Management Physicians. For more information please go to www.Friendslab.com.

**GlaxoSmithKline** Booth #126
Three Franklin Plaza, 1600 Vine Street
Philadelphia, PA 19101
Ph/Fax: 800-366-8900
www.gsk.com

GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Please visit our exhibit to learn more about our products.

**Graham-Massey Analytical Labs, Inc.** Booth #130
50 Todd Road
Shelton, CT 06484
Ph/Fax: 800-288-6365; 203-225-2744
kkilbourn@graham-massey.com • www.grahammassey.com

Graham-Massey Analytical Labs is a full-service medical laboratory dedicated to providing a wide range of quality services – from substance abuse testing to clinical laboratory testing.

**MP Biomedicals** Booth #326
3 Hutton Centre Drive, Suite 100
Santa Ana, CA 92707
Ph/Fax: 888-842-8378; 949-859-5010
David. Katrowski@mpbio.com • www.mpbio.com

MP Biomedicals is a leading world-wide manufacturer of immunodiagnostic products. Our qualitative one-step rapid devices are available in different formats that are highly sensitive with ease of use. We also supply saliva tests for the detection of alcohol.

**Millin Associates LLC** Booth #332
521 Chestnut Street
Cedarhurst, NY 11516
Ph/Fax: 516-374-4530; 516-374-8613
kkilbourn@graham-massey.com • www.grahammassey.com

Millin Associates LLC is the Healthcare Industry’s specialist for converting unpaid Medicaid, Medicaid Managed Care, Medicare Health Insurance and third party claims into paid claims. Equipped with a HIPAA compliant state-of-the-art claims processing system, we provide substantially error-free billing and increased reimbursement for our clients. All fees are contingency based.

**National Institute on Drug Abuse (NIDA)** Booth #210
6001 Executive Blvd., Suite 5213
Bethesda, MD 20892
Ph/Fax: 301-594-6142; 301-443-7397
janel1@nida.nih.gov • www.drugabuse.gov

NIDA is a Federal agency charged with supporting research on the causes, prevention, and treatment of all aspects of drug abuse including AIDS. Results of NIDA-funded research help solve the medical, social, and public health problems of drug abuse and addiction. Publications and research opportunities will be made available.

**Nlatcys** Booth #209
102 Trade Street
Greer, SC 29651
Ph/Fax: 864-416-0153; 864-416-0157
kessex@nlatcys.com • www.methasoft.com

Methasoft® is an industry leading product for the management and provision of care in the opioid treatment arena. Methasoft® is a fully integrated system from patient check-in to kiosk billing. Methasoft® is a fully automated, flexible software that utilizes leading technologies including Microsoft.NET Framework and SQL Server 2005.

**Netalytics** Booth #209
102 Trade Street
Greer, SC 29651
Ph/Fax: 864-416-0153; 864-416-0157
kessex@nlatcys.com • www.methasoft.com

Methasoft® is an industry leading product for the management and provision of care in the opioid treatment arena. Methasoft® is a fully integrated system from patient check-in to kiosk billing. Methasoft® is a fully automated, flexible software that utilizes leading technologies including Microsoft.NET Framework and SQL Server 2005.

**Netalytics** Booth #209
102 Trade Street
Greer, SC 29651
Ph/Fax: 864-416-0153; 864-416-0157
kessex@nlatcys.com • www.methasoft.com

Methasoft® is an industry leading product for the management and provision of care in the opioid treatment arena. Methasoft® is a fully integrated system from patient check-in to kiosk billing. Methasoft® is a fully automated, flexible software that utilizes leading technologies including Microsoft.NET Framework and SQL Server 2005.
**NATIONAL CONFERENCE / APRIL 25 –29, 2009 / HILTON NEW YORK**

**EXHIBITOR DIRECTORY**

**Netsmart Technologies**
3500 Sunrise Highway, Suite D122
Great River, NY 11739
Ph: 800-421-7503
info@ntst.com • www.ntst.com

Netsmart Technologies is the trusted partner for health and human services’ largest connected community of providers and payers. Netsmart Methadone software solutions provide a range of options for both stand-alone methadone clinics and organizations with an integrated methadone treatment program. More than 500 clinics nationwide use Netsmart’s solutions to enhance operational efficiencies, which ultimately lead to improved methadone treatment.

**New York State Office of Alcoholism and Substance Abuse Services (OASAS)**
1450 Western Avenue
Albany, NY 12203
Ph/Fax: 518-473-3460; 518-845-6014
communications@oasas.state.ny.us • www.oasas.state.ny.us

The New York State Office of Alcoholism and Substance Abuse Services (OASAS) oversees one of the nation’s largest addiction services systems, including 1,550 prevention and treatment providers serving 110,000 New Yorkers on any given day. For information on prevention, treatment, recovery in New York State, visit www.oasas.state.ny.us or call 1-877-8-HOPENY.

**NIATx**
Booth #315
1513 University Avenue, Room 4121
Madison, WI 53726
Ph/Fax: 608-263-0063; 608-890-1438
info@niatx.net • www.niatx.net

NIATx is a pioneering improvement collaborative that works with behavioral health organizations across the country. We teach organizations to use a simple process improvement model developed at the University of Wisconsin-Madison. NIATx helps behavioral health payers and providers improve access to and retention in treatment.

**NOVX Systems Inc.**
185 Renfrew Drive
Markham, ON L3R 6G3 Canada
Ph/Fax: 877-879-6689; 905-474-1023
novxinfo@novxsystems.com • www.novxsystems.com

NOVX Systems provides a complete and powerful drug screening solution that allows an informed decision to be made on-site. The FDA cleared iMDx Analyzer quickly provides semi-quantitative results that are automatically uploaded into it’s PatientVu EMR. PatientVu manages results, scheduling, billing, reporting and much more! Start screening smarter and reporting faster today!

**O.Berk of New England / Kols Containers, Inc.**
Booth #215
220 Frontage Road
West Haven, CT 06516
Ph/Fax: 203-912-8000; 203-934-7172
bkursawe@oberk.com • www.oberk.com

O.Berk and Kols are full service packaging distributors. We supply “take-home” bottles and child-resistant caps, as well as tamper-evident seals and dispensing cups. We have warehouses in West Haven, CT and Baltimore, MD with large inventories of bottles and caps to serve your packaging needs.

**OraSure Technologies Inc.**
Booth #108
220 East First Street
Bethlehem, PA 18015
Ph/Fax: 610-882-1820; 610-814-3405
LRomero@OraSure.com • www.orasure.com

OraSure Technologies, Inc., the pioneer of oral fluid drug testing, manufactures and markets the Intercept® Oral Fluid Drug Test System collecting device and diagnostic immunoassays. Intercept combines the ease, efficiency and cost savings of oral fluid collection with significantly increased sample integrity and the accuracy of lab-reliable, proven results.

**Patient Support and Community Education Project**
Booth #233
P.O. Box 26377
Washington, DC 20001
staff@atwatchdog.org
www.atwatchdog.org


**Reckitt Benkiser Pharmaceuticals, Inc.**
Booth #134
10710 Midlothian Turnpike, Suite 430
Richmond, VA 23235
Ph/Fax: 732-919-1234; 732-280-1350

Reckitt Benkiser Pharmaceuticals is at the forefront providing educational resources and treatment options to physicians and patients dealing with the chronic relapsing disease of opioid dependence. Please visit their exhibit where Reckitt Benkiser Managed Care Account Managers will be available to provide scientific information and answer your questions.

**Redwood Toxicology Laboratory, Inc.**
Booth #309
3650 Westwind Blvd
Santa Rosa, CA 95403
Ph/Fax: 707-577-7959; 707-577-8102
sbertulucci@redwoodtoxicology.com • www.redwoodtoxicology.com

At Redwood Toxicology Laboratory, Inc. (RTL), one of the nation’s premier forensic drug testing facilities, we offer you comprehensive, cost effective drug and alcohol testing options. We deliver the certainty of science, the dependability of proven drug screening processes and the assurance of legally defensible results. Our laboratory services include urine drug testing, oral fluid drug testing, prescription drug testing, EtG/EtS alcohol testing, steroid testing and more.

**Roxane Laboratories, Inc.**
Booth #211
1809 Wilson Road
Columbus, OH 43228
Ph/Fax: 614-308-3576
www.roxane.com

Headquartered in Columbus, Ohio, Roxane Laboratories is a recognized leader in researching, manufacturing, and packaging nearly 300 medications including oral liquids, tablets, capsules and cytotoxic pharmaceutical products. Most recently, Roxane acquired the rights to the Cebert Medication Dispensing System. We provide 24/7/365 live answered, quality support by Substance Abuse Technology Professionals. SAMMS is the most cost effective dispensing solution on the Market and quotes can be tailored to meet any budget.

**SAMMS**
Booth #333
510 S. Wesley
Oak Park, IL 60304
Ph/Fax: 877-771-SAMM; 800-789-0954
samms@priceconsultinginc.net • www.sammsystem.com

SAMMS is a fully customizable Electronic Clinic Management and Medication Dispensing System. We provide 24/7/365 live answered, quality support by Substance Abuse Technology Professionals. SAMMS is the most cost effective dispensing solution on the Market and quotes can be tailored to meet any budget.

**San Diego Reference Laboratory**
Booth #208
6122 Nancy Ridge Drive
San Diego, CA 92121
Ph/Fax: 800-677-7995; 858-677-7998
www.sdlrl.com

San Diego Reference Laboratory is a client-focused toxicology laboratory, specializing in drug of abuse testing. We offer specifically designed urine/saliva laboratory panels and cost effective onsite products to accommodate your program’s needs. SDRL offers clients Quality Service, Accurate Test Results, Accessibility to Technical information, and Rapid Turn Around Time.
Siemens Healthcare Diagnostics
1717 Deerfield Road
Deerfield, IL 60015
Ph: 847-267-5300
Kaiyane.byne@siemens.com  •  www.siemens.com/diagnostics
When the stakes are too high to be wrong; turn to the experts in Drug Testing at Siemens Healthcare Diagnostics. Syva EMIT®, is the world’s leading drug monitoring methodology, and Siemens offers a comprehensive portfolio of products for drugs of abuse, specimen validity, point of care testing, and data management.

Smart Software Solutions
66 Pavilion Avenue
Providence, RI 02905
Ph/Fax: 401-780-2300; 401-780-2350
SMART Software Solutions is a premiere provider of computer software for substance abuse treatment. The Smart System is used by over 100 providers throughout the United States and Europe. With 22 of our own facilities, SMART was the distinction of being the only software provider that actually uses its own software.

STERLING Reference Laboratories
2617 East L Street, Suite A
Tacoma, WA 98421-2201
Ph/Fax: 800-442-0438; 253-552-1549
sales@regtox.com  •  www.sterlingreflabs.com
STERLING Reference Laboratories is an established methadone – experienced toxicology laboratory testing for drugs of abuse, delivering responsive service and affordable prices. SRL is unique, offering customized drug testing services to meet each customers needs and live access to our Scientists regarding drug testing. Call 1-800-442-0438 to learn more!

Substance Abuse and Mental Health Services Administration
11300 Rockville Pike
Rockville, MD 20852
Ph/Fax: 204-221-4056; 301-945-4296
request@samhsaexhibits.org  •  www.samhsa.gov
SAMHSA is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity and effectiveness of the nation’s substance abuse and prevention, addictions treatment, and mental health services delivery system.

The Joint Commission
One Renaissance Blvd
Oakbrook Terrace, IL 60181
Ph/Fax: 630-792-5866; 630-792-4866
echoi@jointcommission.org  •  www.jointcommission.org/BHC
Accreditation from The Joint Commission helps create a standards-based culture of excellence, assisting you in providing the safest, highest quality environment for those you serve. To learn more about how your organization can earn this respected “Gold Seal of Approval™,” drop by booth #235, visit www.goldsealofapproval.org or call (630) 792-5866.

Tower Systems, Inc.
17461 Irvine Blvd, Suite Y
Tustin, CA 92780
Ph/Fax: 714-731-0491; 714-731-8637
jnieslen@towersys.com  •  www.methadoneclinics.com
If you’re tired of hearing unfulfilled promises or relying on software that has yet to be delivered, it’s time to open your eyes and take a good look at Tower Systems. With a host of CARF, JCAHO & COA accreditation tools, as well as HIPAA compliant 837 & 835 billing, it’s time to open your eyes and take a good look at Tower Systems.

Willow Laboratories
280 Union Street
Lynn, MA 01901
Ph/Fax: 800-638-3030 (US, Canada) or 301-223-2300; 301-223-2400
customerservice@LWW.com  •  www.LWW.com
Willow Laboratories offers comprehensive laboratory based drug testing services including GC/MS and LC/MS/MS confirmations. In addition to our urine drug screening, we provide hair and saliva testing. Willow maintains a staff of pharmacologists, toxicologists, physicians, and certified medical technologists. Clients can access results online through www.willowlabs.com or directly with EMR.

Wolters Kluwer Health/Lippincott
530 Walnut Street
Philadelphia, PA 19106
Ph/Fax: 800-668-3030 (US, Canada) or 301-223-2300; 301-223-2400
info@willowlabs.com  •  www.willowlabs.com
Willow Laboratories offers comprehensive laboratory based drug testing services including GC/MS and LC/MS/MS confirmations. In addition to our urine drug screening, we provide hair and saliva testing. Willow maintains a staff of pharmacologists, toxicologists, physicians, and certified medical technologists. Clients can access results online through www.willowlabs.com or directly with EMR.

White Deer Run/Cove Forge Behavioral Health System
204 East Calder Way, Suite 306
State College, PA 16801
Ph/Fax: 814-861-6198; 814-861-6199
kkoptchak@crchealth.com  •  www.whitedeerun.com
White Deer Run/Cove Forge Behavioral Health System/Cove Forge Behavioral Health System is one of the leading systems in the nation for the treatment of drug and alcohol addiction. Each of our facilities provides a relaxed atmosphere that lends itself to personal reflection and healing for adults and adolescents alike.

VistaPharm
2224 Cahaba Valley Drive, Suite B3
Birmingham, AL 35242
Ph/Fax: 205-981-1387; 205-980-4849
info@vistapharm.com  •  www.vistapharm.com
VistaPharm manufactures and distributes quality methadone products. We offer oral concentrate, dispersible tablets, tablets, and powder methadone. Our personalized services set us apart in our industry. We are accessible to address your needs in an expedient manner. Stop by our booth to meet the VistaPharm team.

VistaPharm manufactures and distributes quality methadone products. We offer oral concentrate, dispersible tablets, tablets, and powder methadone. Our personalized services set us apart in our industry. We are accessible to address your needs in an expedient manner. Stop by our booth to meet the VistaPharm team.

AloD
American Association for the Treatment of Opioid Dependence, Inc.
Treatment & Recovery: People & Outcomes
SPECIAL THANKS

The American Association for the Treatment of Opioid Dependence, Inc. and the 2009 Conference Planning Committee acknowledge and give special thanks to:

COMPA – New York State’s Opioid Treatment Coalition

National Institutes of Health (NIH) – National Institute on Drug Abuse (NIDA)

New York State Office of Alcoholism and Substance Abuse Services (OASAS)

Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT)

PLATINUM LEVEL SPONSOR
Covidien-Mallinckrodt

GOLD LEVEL SPONSORS
Bendiner & Schlesinger, Inc.
VistaPharm, Inc.

SILVER LEVEL SPONSORS
Addiction Treatment Providers Insurance Program
Colonial Management, LP
David Szerlip & Associates, Inc.
GlaxoSmithKline
Netsmart Technologies
OraSure Technologies, Inc.
Reckitt Benckiser Pharmaceuticals, Inc.
Roxane Laboratories, Inc.
Smart Software Solutions

BRONZE LEVEL SPONSORS
O. Berk Co. of New England Kols Containers, Inc.
Tower Systems, Inc.
2009 Continuing Medical Education – 31.75

ASAM
“This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society of Addiction Medicine (ASAM) and American Association for the Treatment of Opioid Dependence (AATOD).

The American Society of Addiction Medicine designates this educational activity for a maximum of 31.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

2009 Continuing Education Hours - 33.25

NAADAC – “AATOD is an approved provider through NAADAC, the Association for Addiction Professionals, Provider #000218. This program meets the criteria for up to 33.25 hours of continuing education.”

NY OASAS – The New York State Office of Alcoholism and Substance Abuse Services’ (OASAS) recognizes the approval by NAADAC and, as such, all relevant/training will be acceptable for CASAC, CPP and/or CPS initial credentialing and/or renewal clock hours.

NBCC – “This program has been approved by the National Board for Certified Counselors for up to 33.25 hours, Approval Number SP-1631.”

ASWB – AATOD, provider # 1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. AATOD maintains responsibility for the program approved until 2010. Social workers will receive up to 33.25 continuing education clock hours.

AATOD has applied to the following organization for continuing education approval:

New York State Nurses’ Association (NYSNA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Plan to join us again!
October 23–27, 2010 in Chicago